Protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcineurin	B-protein
synergize	O
to	O
activate	O
IkappaB	B-protein
kinase	I-protein
and	O
NF-kappaB	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

The	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF-kappaB	B-protein
)	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
that	O
is	O
key	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O

T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
cross-linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF-kappaB	B-protein
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-protein
.	O

By	O
using	O
Jurkat	B-cell_line
and	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	B-protein
-initiated	O
signal	O
transduction	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
calcineurin	B-protein
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	B-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
complex	I-protein
but	O
not	O
of	O
another	O
putative	B-protein
IkappaBalpha	I-protein
kinase	I-protein
,	O
p90	B-protein
(	I-protein
rsk	I-protein
)	I-protein
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	B-protein
complex	I-protein
,	O
but	O
not	O
p90	B-protein
(	I-protein
rsk	I-protein
)	I-protein
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	B-protein
mediated	O
by	O
the	O
co-activation	O
of	O
PKC	B-protein
and	O
calcineurin	B-protein
.	O

Each	O
second	O
messenger	O
is	O
necessary	O
,	O
as	O
inhibition	O
of	O
either	O
one	O
reverses	O
the	O
activation	O
of	O
the	O
IKK	B-protein
complex	I-protein
and	O
IkappaBalpha	B-protein
phosphorylation	O
in	O
vivo	O
.	O

Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	B-protein
and	I-protein
-beta	I-protein
demonstrates	O
that	O
only	O
IKKbeta	B-protein
is	O
the	O
target	O
for	O
PKC	B-protein
and	O
calcineurin	B-protein
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR	B-protein
/CD3	B-protein
signal	O
transduction	O
pathway	O
both	O
PKC	B-protein
and	O
calcineurin	B-protein
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	B-protein
complex	I-protein
and	O
NF-kappaB	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

33	NULL
,	NULL
Issue	NULL
of	NULL
August	NULL
13	NULL
,	NULL
pp	NULL
.	NULL

22923-22931	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

Protein	NULL
Kinase	NULL
C	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IxB	NULL
Kinase	NULL
and	NULL
NF-KB	NULL
in	NULL
T	NULL
Lymphocytes*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
25	NULL
,	NULL
1999	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
May	NULL
5	NULL
,	NULL
1999	NULL
)	NULL
Sergey	NULL
A.	NULL
Kevin	NULL
N.	NULL
Pennington	NULL
}	NULL
,	NULL
Alicia	NULL
and	NULL
Carlos	NULL
V.	NULL
Payaf§1	NULL
From	NULL
the	NULL
{	NULL
Department	NULL
of	NULL
Immunology	NULL
and	NULL
the	NULL
§Division	NULL
of	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Mayo	NULL
Clinic	NULL
,	NULL
Rochester	NULL
,	NULL
Minnesota	NULL
55905	NULL
The	NULL
nuclear	NULL
factor	NULL
of	NULL
«	NULL
B	NULL
is	NULL
a	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
key	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
inflammation	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
cross-linking	NULL
is	NULL
in	NULL
part	NULL
required	NULL
for	NULL
activation	NULL
of	NULL
NF-KB	NULL
,	NULL
which	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
IxBa	NULL
.	NULL

By	NULL
using	NULL
Jurkat	NULL
and	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
simultaneous	NULL
activation	NULL
of	NULL
two	NULL
second	NULL
messengers	NULL
of	NULL
the	NULL
TCR-initiated	NULL
signal	NULL
transduction	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
calcineurin	NULL
,	NULL
results	NULL
in	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
IxBa	NULL
kinase	NULL
(	NULL
IKK	NULL
)	NULL
complex	NULL
but	NULL
not	NULL
of	NULL
another	NULL
putative	NULL
IxBa	NULL
kinase	NULL
,	NULL
p90'**	NULL
.	NULL

We	NULL
also	NULL
demonstrate	NULL
that	NULL
the	NULL
IKK	NULL
complex	NULL
,	NULL
but	NULL
not	NULL
p90'**	NULL
,	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
in	NULL
vivo	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
mediated	NULL
by	NULL
the	NULL
co-activation	NULL
of	NULL
PKC	NULL
and	NULL
calcineurin	NULL
.	NULL

Each	NULL
second	NULL
messenger	NULL
is	NULL
nec-essary	NULL
,	NULL
as	NULL
inhibition	NULL
of	NULL
either	NULL
one	NULL
reverses	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
and	NULL
IxBa	NULL
phosphorylation	NULL
in	NULL
vivo	NULL
.	NULL

Overexpression	NULL
of	NULL
dominant	NULL
negative	NULL
forms	NULL
of	NULL
IKKa	NULL
and	NULL
-B	NULL
demonstrates	NULL
that	NULL
only	NULL
IKK	NULL
is	NULL
the	NULL
target	NULL
for	NULL
PKC	NULL
and	NULL
calcineurin	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
within	NULL
the	NULL
TCR/CD3	NULL
signal	NULL
transduction	NULL
pathway	NULL
both	NULL
PKC	NULL
and	NULL
calcineurin	NULL
are	NULL
required	NULL
for	NULL
the	NULL
effective	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
and	NULL
NF-xB	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
molecular	NULL
events	NULL
that	NULL
ensue	NULL
in	NULL
T	NULL
lymphocytes	NULL
following	NULL
antigen	NULL
presentation	NULL
is	NULL
paramount	NULL
to	NULL
understanding	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

The	NULL
signal	NULL
transduction	NULL
pathways	NULL
triggered	NULL
by	NULL
antigen	NULL
presentation	NULL
lead	NULL
to	NULL
the	NULL
immediate	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
further	NULL
amplify	NULL
the	NULL
process	NULL
of	NULL
lymphocyte	NULL
activation	NULL
,	NULL
ultimately	NULL
leading	NULL
to	NULL
cell	NULL
proliferation	NULL
and	NULL
division	NULL
.	NULL

Dysregulation	NULL
of	NULL
this	NULL
process	NULL
results	NULL
in	NULL
T	NULL
lymphocyte	NULL
anergy	NULL
,	NULL
autoimmunity	NULL
,	NULL
and	NULL
disruption	NULL
of	NULL
T	NULL
lymphocyte	NULL
homeostasis	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Two	NULL
additional	NULL
settings	NULL
that	NULL
would	NULL
benefit	NULL
from	NULL
a	NULL
better	NULL
understanding	NULL
of	NULL
the	NULL
molecular	NULL
events	NULL
triggered	NULL
by	NULL
T	NULL
cell	NULL
activation	NULL
are	NULL
viral	NULL
pathogenesis	NULL
and	NULL
drug	NULL
discovery	NULL
.	NULL

For	NULL
example	NULL
,	NULL
HIV	NULL
integrates	NULL
in	NULL
the	NULL
chromosome	NULL
of	NULL
T	NULL
lymphocytes	NULL
where	NULL
it	NULL
remains	NULL
latent	NULL
.	NULL

Its	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Training	NULL
Grant	NULL
CAQ9127	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
RO1	NULL
AI86076	NULL
,	NULL
and	NULL
the	NULL
Mayo	NULL
Foundation	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

«	NULL
To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Mayo	NULL
Clinic	NULL
,	NULL
200	NULL
First	NULL
St.	NULL
SW	NULL
,	NULL
Guggenheim	NULL
501	NULL
,	NULL
Rochester	NULL
,	NULL
MN	NULL
55905	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
507-284-8747	NULL
;	NULL
Fax	NULL
:	NULL
507-284-8757	NULL
;	NULL
E-mail	NULL
:	NULL
paya	NULL
@	NULL
mayo.edu	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
HIV	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
IKKa	NULL
,	NULL
IxBa	NULL
kinases	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin-2	NULL
;	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
«	NULL
B	NULL
;	NULL
GST	NULL
,	NULL
glutathione	NULL
S-transferase	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyl-transferase	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
TNFR	NULL
,	NULL
TNF	NULL
receptor	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
WCE	NULL
,	NULL
whole-cell	NULL
extract	NULL
;	NULL
DN	NULL
,	NULL
dominant	NULL
negative	NULL
;	NULL
wt	NULL
,	NULL
wild	NULL
type	NULL
;	NULL
KD	NULL
,	NULL
kinase	NULL
dead	NULL
;	NULL
MEK	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase/extracellular	NULL
signal-regulated	NULL
kinase	NULL
;	NULL
GF	NULL
,	NULL
GF109203X	NULL
;	NULL
Go	NULL
,	NULL
G6	NULL
6976	NULL
;	NULL
PD	NULL
,	NULL
PD	NULL
098059	NULL
;	NULL
IVK	NULL
,	NULL
in	NULL
vitro	NULL
kinase	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
reactivation	NULL
by	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
activated	NULL
following	NULL
T	NULL
cell	NULL
receptor	NULL
cross-linking	NULL
is	NULL
relevant	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
AIDS	NULL
(	NULL
8	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
development	NULL
of	NULL
improved	NULL
immunosuppressive	NULL
agents	NULL
that	NULL
target	NULL
T	NULL
cell	NULL
function	NULL
will	NULL
be	NULL
accelerated	NULL
by	NULL
identifying	NULL
the	NULL
exact	NULL
molecular	NULL
events	NULL
that	NULL
result	NULL
from	NULL
the	NULL
molecular	NULL
events	NULL
regulating	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Effective	NULL
antigen	NULL
presentation	NULL
to	NULL
T	NULL
lymphocytes	NULL
involves	NULL
not	NULL
only	NULL
the	NULL
engagement	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor-CD3	NULL
complex	NULL
but	NULL
also	NULL
other	NULL
receptors	NULL
that	NULL
mediate	NULL
co-activation	NULL
signals	NULL
such	NULL
as	NULL
CD28	NULL
.	NULL

How	NULL
these	NULL
two	NULL
separate	NULL
signal	NULL
transduction	NULL
pathways	NULL
(	NULL
TCR/CD3	NULL
and	NULL
CD28	NULL
)	NULL
converge	NULL
to	NULL
result	NULL
in	NULL
the	NULL
maximal	NULL
activation	NULL
of	NULL
the	NULL
T	NULL
lymphocyte	NULL
is	NULL
under	NULL
active	NULL
study	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
by	NULL
its	NULL
cognate	NULL
peptide-major	NULL
histo-compatibility	NULL
complex	NULL
induces	NULL
phospholipase	NULL
C	NULL
activation	NULL
which	NULL
hydrolyzes	NULL
phosphatidylinositol	NULL
4,5-bisphosphate	NULL
to	NULL
inositol	NULL
1,4,5-triphosphate	NULL
and	NULL
diacylglycerol	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Diacylglycerol	NULL
activates	NULL
protein	NULL
kinases	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
whereas	NULL
inositol	NULL
1,4,5-triphosphate	NULL
leads	NULL
to	NULL
the	NULL
release	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
stores	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
same	NULL
cellular	NULL
events	NULL
initiated	NULL
by	NULL
phospholipase	NULL
C	NULL
activation	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
treatment	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
a	NULL
Ca**	NULL
``	NULL
ionophore	NULL
that	NULL
raises	NULL
intracellular	NULL
Ca**	NULL
levels	NULL
and	NULL
phorbol	NULL
esters	NULL
that	NULL
activate	NULL
PKC	NULL
isoforms	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Free	NULL
intracellular	NULL
Ca**	NULL
targets	NULL
the	NULL
Ca	NULL
``	NULL
*/calmodulin-activated	NULL
phos-phatase	NULL
calcineurin	NULL
which	NULL
mediates	NULL
a	NULL
critical	NULL
positive	NULL
signal	NULL
necessary	NULL
for	NULL
IL-2	NULL
induction	NULL
through	NULL
its	NULL
synergy	NULL
with	NULL
PKC	NULL
activation	NULL
,	NULL
synergy	NULL
that	NULL
can	NULL
be	NULL
reversed	NULL
by	NULL
targeting	NULL
calcineurin	NULL
with	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

The	NULL
initial	NULL
studies	NULL
that	NULL
investigated	NULL
the	NULL
targets	NULL
of	NULL
the	NULL
synergy	NULL
between	NULL
PKC	NULL
and	NULL
calcineurin	NULL
identified	NULL
the	NULL
transcription	NULL
factors	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
nuclear	NULL
factor	NULL
of	NULL
«	NULL
B	NULL
(	NULL
NF-kB	NULL
)	NULL
(	NULL
9	NULL
,	NULL
10	NULL
,	NULL
11	NULL
)	NULL
,	NULL
as	NULL
being	NULL
activated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
these	NULL
separate	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
heterodimer	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
belong	NULL
to	NULL
the	NULL
Rel	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

The	NULL
canonical	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
heterodimer	NULL
of	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
with	NULL
p50	NULL
or	NULL
p52	NULL
(	NULL
12	NULL
,	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

This	NULL
heterodimer	NULL
is	NULL
anchored	NULL
by	NULL
a	NULL
group	NULL
of	NULL
proteins	NULL
named	NULL
IB	NULL
,	NULL
which	NULL
function	NULL
to	NULL
retain	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
cytosol	NULL
by	NULL
masking	NULL
its	NULL
nuclear	NULL
localization	NULL
signal	NULL
(	NULL
15-18	NULL
)	NULL
.	NULL

IxBa	NULL
is	NULL
a	NULL
prototype	NULL
IB	NULL
molecule	NULL
known	NULL
to	NULL
control	NULL
the	NULL
subcellular	NULL
localization	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
p50/p65	NULL
)	NULL
.	NULL

Following	NULL
activation	NULL
of	NULL
certain	NULL
signal	NULL
transduction	NULL
pathways	NULL
,	NULL
a	NULL
site-specific	NULL
hyperphosphorylation	NULL
of	NULL
IxBa	NULL
«	NULL
at	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
renders	NULL
the	NULL
inhibitor	NULL
molecule	NULL
susceptible	NULL
to	NULL
site-specific	NULL
ubiquitination	NULL
and	NULL
subsequent	NULL
degradation	NULL
by	NULL
the	NULL
proteasome	NULL
complex	NULL
(	NULL
19-23	NULL
)	NULL
.	NULL

This	NULL
releases	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
undergo	NULL
nuclear	NULL
translocation	NULL
.	NULL

Two	NULL
novel	NULL
IxBa	NULL
kinases	NULL
,	NULL
IKKa	NULL
(	NULL
24-26	NULL
)	NULL
and	NULL
IKKS	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
,	NULL
contained	NULL
within	NULL
a	NULL
high	NULL
molecular	NULL
weight	NULL
complex	NULL
termed	NULL
the	NULL
signalsome	NULL
target	NULL
the	NULL
phosphorylation	NULL
of	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
of	NULL
IxBa	NULL
and	NULL
mediate	NULL
the	NULL
TNF-	NULL
@	NULL
-induced	NULL
IxBa	NULL
hyperphosphorylation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

An	NULL
additional	NULL
N-terminal	NULL
IxBa	NULL
kinase	NULL
,	NULL
the	NULL
mitogen-activated	NULL
riboso-mal	NULL
S6	NULL
protein	NULL
kinase	NULL
RSK-1	NULL
or	NULL
p90'®*	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
.	NULL

to	NULL
mediate	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
phorbol	NULL
esters	NULL
and	NULL
to	NULL
229283	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
22924	NULL
phosphorylate	NULL
I	NULL
«	NULL
Ba	NULL
preferentially	NULL
at	NULL
Ser-32	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL

However	NULL
,	NULL
its	NULL
functional	NULL
relevance	NULL
in	NULL
vivo	NULL
is	NULL
yet	NULL
unclear	NULL
(	NULL
80	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
addressing	NULL
how	NULL
the	NULL
PKC-	NULL
and	NULL
calcineurin-dependent	NULL
signal	NULL
transduction	NULL
pathways	NULL
triggered	NULL
by	NULL
TCR	NULL
CD3	NULL
cross-linking	NULL
lead	NULL
to	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
identified	NULL
IxBa	NULL
as	NULL
a	NULL
target	NULL
molecule	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Whereas	NULL
PKC	NULL
activation	NULL
by	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
moderate	NULL
degree	NULL
of	NULL
IxBa	NULL
hyperphosphorylation-degradation	NULL
and	NULL
activated	NULL
calcineurin	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
IxBa	NULL
,	NULL
the	NULL
combined	NULL
activation	NULL
of	NULL
these	NULL
two	NULL
second	NULL
messengers	NULL
leads	NULL
to	NULL
a	NULL
synergistic	NULL
and	NULL
highly	NULL
effective	NULL
hyperphosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
IxBa	NULL
(	NULL
81	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
whereas	NULL
TCR	NULL
and	NULL
TNFR	NULL
triggered	NULL
separate	NULL
signal	NULL
transduction	NULL
pathways	NULL
,	NULL
both	NULL
ultimately	NULL
target	NULL
IxBa	NULL
,	NULL
and	NULL
the	NULL
use	NULL
of	NULL
specific	NULL
inhibitors	NULL
of	NULL
calcineurin	NULL
and	NULL
PKC	NULL
enabled	NULL
the	NULL
separation	NULL
of	NULL
the	NULL
signaling	NULL
pathways	NULL
of	NULL
TCR	NULL
and	NULL
TNFR	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Despite	NULL
this	NULL
novel	NULL
observation	NULL
,	NULL
the	NULL
mechanisms	NULL
whereby	NULL
two	NULL
separate	NULL
second	NULL
messengers	NULL
,	NULL
PKC	NULL
and	NULL
calcineurin	NULL
,	NULL
lead	NULL
to	NULL
the	NULL
lymphocyte-specific	NULL
hyperphosphorylation	NULL
of	NULL
IxBa	NULL
remains	NULL
unknown	NULL
.	NULL

The	NULL
recent	NULL
identification	NULL
of	NULL
the	NULL
N-terminal	NULL
IxBa	NULL
provides	NULL
the	NULL
opportunity	NULL
to	NULL
advance	NULL
in	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
,	NULL
whereas	NULL
signal	NULL
transduction	NULL
pathways	NULL
triggered	NULL
by	NULL
TCR/CD3	NULL
cross-linking	NULL
,	NULL
separate	NULL
from	NULL
those	NULL
downstream	NULL
of	NULL
CD28	NULL
,	NULL
lead	NULL
to	NULL
IxBa	NULL
degradation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
synergy	NULL
between	NULL
two	NULL
second	NULL
messengers	NULL
of	NULL
the	NULL
TCR/CD3	NULL
pathways	NULL
,	NULL
PKC	NULL
and	NULL
calcineurin	NULL
,	NULL
as	NULL
regulators	NULL
of	NULL
the	NULL
N-terminal	NULL
IxBa	NULL
kinases	NULL
.	NULL

By	NULL
using	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
and	NULL
T	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
PKC-	NULL
and	NULL
Ca**-dependent	NULL
pathways	NULL
synergistically	NULL
activate	NULL
both	NULL
the	NULL
IKK	NULL
complex	NULL
and	NULL
p90'**	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
,	NULL
p90	NULL
``	NULL
®*	NULL
activation	NULL
is	NULL
calcineurin-independent	NULL
,	NULL
and	NULL
only	NULL
the	NULL
IKK	NULL
complex	NULL
(	NULL
IKK	NULL
)	NULL
but	NULL
not	NULL
p90'**	NULL
mediates	NULL
I	NULL
«	NULL
xBa	NULL
phosphorylation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
vivo	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
signalsome	NULL
by	NULL
PKC	NULL
and	NULL
calcineurin	NULL
is	NULL
inhibited	NULL
by	NULL
either	NULL
calcineurin-	NULL
or	NULL
PKC-specific	NULL
inhibitors	NULL
suggesting	NULL
that	NULL
either	NULL
signal	NULL
transduction	NULL
pathway	NULL
is	NULL
required	NULL
and	NULL
essential	NULL
for	NULL
effectively	NULL
activating	NULL
the	NULL
IKK	NULL
complex	NULL
and	NULL
,	NULL
hence	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Plasmids-The	NULL
«	NULL
B-lue	NULL
reporter	NULL
plasmid	NULL
consists	NULL
of	NULL
three	NULL
kB	NULL
con-catamers	NULL
from	NULL
the	NULL
HIV-long	NULL
terminal	NULL
repeat	NULL
cloned	NULL
upstream	NULL
of	NULL
a	NULL
concanavalin-A	NULL
minimal	NULL
promoter	NULL
driving	NULL
the	NULL
expression	NULL
of	NULL
luciferase	NULL
(	NULL
82	NULL
)	NULL
.	NULL

The	NULL
pREP4/CAT	NULL
plasmid	NULL
,	NULL
which	NULL
consists	NULL
of	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter-enhancer	NULL
driving	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
(	NULL
Invitrogen	NULL
,	NULL
Carlsbad	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

IKKS	NULL
KD	NULL
(	NULL
K44A	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
M.	NULL
Roth	NULL
(	NULL
Tularik	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

IKKa	NULL
kinase	NULL
dead	NULL
(	NULL
KD	NULL
)	NULL
(	NULL
D144N	NULL
)	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
Alain	NULL
Israel	NULL
,	NULL
Institute	NULL
Pasteur	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
.	NULL

Wild-type	NULL
PKCa	NULL
cDNA	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Altman	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
.	NULL

The	NULL
expression	NULL
vector	NULL
,	NULL
pSRa4ACaM-AI	NULL
,	NULL
encoding	NULL
a	NULL
constitutively	NULL
active	NULL
calcineurin	NULL
catalytic	NULL
subunit	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
previously	NULL
described	NULL
pSRa-ACaM-AI	NULL
(	NULL
9	NULL
)	NULL
except	NULL
that	NULL
it	NULL
contains	NULL
an	NULL
additional	NULL
75	NULL
base	NULL
pairs	NULL
of	NULL
5'-untranslated	NULL
sequence	NULL
from	NULL
CN4a	NULL
(	NULL
84	NULL
)	NULL
.	NULL

Cell	NULL
Culture	NULL
and	NULL
Reagents-Jurkat	NULL
T	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Tissue	NULL
Culture	NULL
Collection	NULL
,	NULL
Manassas	NULL
,	NULL
VA	NULL
,	NULL
and	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin/streptomy-cin	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
cells	NULL
were	NULL
grown	NULL
to	NULL
a	NULL
density	NULL
of	NULL
8-5	NULL
x	NULL
10°/ml	NULL
at	NULL
the	NULL
time	NULL
of	NULL
the	NULL
different	NULL
experiments	NULL
.	NULL

PMA	NULL
,	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
p-nitrophenyl	NULL
phosphate	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Ionomycin	NULL
,	NULL
GF109203X	NULL
(	NULL
GF	NULL
)	NULL
,	NULL
Go	NULL
6976	NULL
,	NULL
B-glycerophosphate	NULL
,	NULL
PD	NULL
098059	NULL
were	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
,	NULL
and	NULL
TNF	NULL
was	NULL
purchased	NULL
from	NULL
Genzyme	NULL
(	NULL
Bos-ton	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Leupeptin	NULL
,	NULL
aprotinin	NULL
,	NULL
and	NULL
pepstatin	NULL
A	NULL
were	NULL
obtained	NULL
from	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
.	NULL

Anti-IKKa	NULL
(	NULL
H-744	NULL
,	NULL
M-280	NULL
)	NULL
,	NULL
(	NULL
H-470	NULL
)	NULL
,	NULL
anti-Raf-1	NULL
(	NULL
C-12	NULL
)	NULL
,	NULL
anti-Rsk-1	NULL
(	NULL
C-21	NULL
)	NULL
,	NULL
and	NULL
anti-IxBa	NULL
(	NULL
C-21	NULL
)	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
.	NULL

Anti-human	NULL
CD3	NULL
antibodies	NULL
were	NULL
obtained	NULL
from	NULL
Ancell	NULL
,	NULL
Bayport	NULL
,	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
MN	NULL
.	NULL

Neutralizing	NULL
antibodies	NULL
to	NULL
TNF	NULL
were	NULL
purchased	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

To	NULL
isolate	NULL
CD3*	NULL
T	NULL
cells	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
from	NULL
healthy	NULL
donors	NULL
were	NULL
obtained	NULL
from	NULL
buffy	NULL
coats	NULL
by	NULL
density	NULL
gradient	NULL
centrifugation	NULL
(	NULL
Ficoll-Paque	NULL
,	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
then	NULL
depleted	NULL
of	NULL
monocytes	NULL
by	NULL
two	NULL
cycles	NULL
of	NULL
plastic	NULL
adherence	NULL
,	NULL
and	NULL
CD3*	NULL
T	NULL
cells	NULL
were	NULL
purified	NULL
by	NULL
neura-minidase-treated	NULL
sheep	NULL
red	NULL
blood	NULL
cell	NULL
rosetting	NULL
.	NULL

The	NULL
remaining	NULL
cell	NULL
population	NULL
was	NULL
repeatedly	NULL
found	NULL
to	NULL
be	NULL
98	NULL
%	NULL
CD3*	NULL
T	NULL
cells	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
analysis	NULL
.	NULL

CD3*	NULL
T	NULL
cells	NULL
used	NULL
in	NULL
the	NULL
various	NULL
experiments	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Invitrogen	NULL
,	NULL
Carlsbad	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
antibiotics	NULL
(	NULL
penicillin	NULL
100	NULL
units/ml	NULL
,	NULL
streptomycin	NULL
100	NULL
pg/ml	NULL
)	NULL
at	NULL
0.5	NULL
x	NULL
10°	NULL
cells/ml	NULL
.	NULL

CD3*	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
and	NULL
harvested	NULL
on	NULL
the	NULL
2nd	NULL
day	NULL
after	NULL
isolation	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
2	NULL
uM	NULL
GF109203X	NULL
and	NULL
Go	NULL
6976	NULL
for	NULL
15	NULL
min	NULL
,	NULL
30	NULL
um	NULL
PD	NULL
098059	NULL
for	NULL
20	NULL
min	NULL
.	NULL

FK506	NULL
was	NULL
used	NULL
at	NULL
20	NULL
ng/ml	NULL
.	NULL

For	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
PMA	NULL
was	NULL
used	NULL
at	NULL
20	NULL
ng/ml	NULL
,	NULL
ionomycin	NULL
at	NULL
8.5	NULL
ug/ml	NULL
,	NULL
and	NULL
TNF-	NULL
@	NULL
at	NULL
10	NULL
ng/ml	NULL
.	NULL

For	NULL
CD3*	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
PMA	NULL
was	NULL
used	NULL
at	NULL
2.5	NULL
ng/ml	NULL
,	NULL
ionomycin	NULL
at	NULL
0.7	NULL
ug/ml	NULL
,	NULL
and	NULL
TNF-	NULL
@	NULL
at	NULL
10	NULL
ng/ml	NULL
.	NULL

TCR/CD3	NULL
cross-linking	NULL
was	NULL
performed	NULL
with	NULL
3	NULL
ug/ml	NULL
anti-CD3	NULL
antibody	NULL
as	NULL
previously	NULL
demonstrated	NULL
by	NULL
our	NULL
group	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Cell	NULL
Extract	NULL
Preparation	NULL
,	NULL
Immunoblotting	NULL
Kinase	NULL
Assay-To	NULL
obtain	NULL
total	NULL
cellular	NULL
proteins	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
resuspended	NULL
in	NULL
whole-cell	NULL
extract	NULL
PD	NULL
buffer	NULL
adapted	NULL
with	NULL
slight	NULL
modifications	NULL
from	NULL
Mercurio	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
(	NULL
40	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
8	NULL
,	NULL
0.3	NULL
M	NULL
NaCl	NULL
,	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
6	NULL
mM	NULL
EDTA	NULL
,	NULL
6	NULL
mm	NULL
EGTA	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
10	NULL
mM	NULL
p-nitrophenyl	NULL
phosphate	NULL
,	NULL
10	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
300	NULL
pM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
2	NULL
uM	NULL
phenylmethylsulfonyl	NULL
fluo-ride	NULL
,	NULL
aprotinin	NULL
at	NULL
10	NULL
ug/ml	NULL
,	NULL
leupeptin	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
pepstatin	NULL
1	NULL
ug/ml	NULL
)	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
12,000	NULL
X	NULL
g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
resultant	NULL
supernatant	NULL
contained	NULL
total	NULL
cellular	NULL
protein	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
cellular	NULL
protein	NULL
present	NULL
in	NULL
the	NULL
clarified	NULL
supernatant	NULL
was	NULL
calculated	NULL
by	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
.	NULL

For	NULL
Western	NULL
immunoblots	NULL
,	NULL
equal	NULL
amounts	NULL
of	NULL
whole	NULL
cell	NULL
extract	NULL
(	NULL
WCE	NULL
)	NULL
protein	NULL
were	NULL
loaded	NULL
and	NULL
separated	NULL
by	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon-P	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Immunoblotting	NULL
was	NULL
performed	NULL
with	NULL
specific	NULL
antibodies	NULL
and	NULL
visualized	NULL
by	NULL
using	NULL
the	NULL
ECL	NULL
Western	NULL
blotting	NULL
detection	NULL
kit	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

For	NULL
the	NULL
immunocomplex	NULL
kinase	NULL
assay	NULL
,	NULL
100	NULL
ug	NULL
of	NULL
Jurkat	NULL
WCE	NULL
and	NULL
50	NULL
ug	NULL
of	NULL
CD3*	NULL
T	NULL
cell	NULL
WCE	NULL
were	NULL
rotated	NULL
with	NULL
specific	NULL
antibodies	NULL
for	NULL
1	NULL
h	NULL
and	NULL
then	NULL
for	NULL
an	NULL
additional	NULL
1	NULL
h	NULL
more	NULL
with	NULL
protein	NULL
A-agarose	NULL
beads	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
immunoprecipitations	NULL
were	NULL
performed	NULL
in	NULL
WCE	NULL
buffer	NULL
with	NULL
high	NULL
NaCl	NULL
concentrations	NULL
(	NULL
0.5	NULL
M	NULL
)	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
0.5	NULL
M	NULL
NaCl	NULL
WCE	NULL
buffer	NULL
followed	NULL
by	NULL
1	NULL
wash	NULL
of	NULL
kinase	NULL
assay	NULL
washing	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
40	NULL
mM	NULL
NaCl	NULL
)	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
mixed	NULL
with	NULL
15	NULL
pl	NULL
of	NULL
kinase	NULL
buffer	NULL
(	NULL
83	NULL
)	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7	NULL
4	NULL
,	NULL
2	NULL
mM	NULL
magnesium	NULL
chloride	NULL
,	NULL
2	NULL
mM	NULL
manganese	NULL
chloride	NULL
,	NULL
10	NULL
uM	NULL
ATP	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
10	NULL
mM	NULL
p-nitrophenyl	NULL
phosphate	NULL
,	NULL
10	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
300	NULL
pM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
2	NULL
uM	NULL
phenylmethylsulfony	NULL
]	NULL
fluo-ride	NULL
,	NULL
aprotinin	NULL
at	NULL
10	NULL
pg/ml	NULL
,	NULL
leupeptin	NULL
at	NULL
1	NULL
pg/ml	NULL
,	NULL
pepstatin	NULL
at	NULL
1	NULL
ug/ml	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
)	NULL
containing	NULL
2	NULL
ug	NULL
of	NULL
GST-IxBa-	NULL
(	NULL
1-53	NULL
)	NULL
substrate	NULL
and	NULL
1	NULL
uCi	NULL
of	NULL
[	NULL
y-	NULL
``	NULL
``	NULL
PJATP	NULL
.	NULL

The	NULL
80-min	NULL
kinase	NULL
reaction	NULL
at	NULL
30	NULL
°C	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
4X	NULL
SDS-PAGE	NULL
sample	NULL
buffer	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon-P	NULL
membrane	NULL
.	NULL

The	NULL
top	NULL
part	NULL
of	NULL
the	NULL
membrane	NULL
was	NULL
used	NULL
for	NULL
immunoblots	NULL
of	NULL
IKKa	NULL
or	NULL
Rsk-1	NULL
;	NULL
on	NULL
the	NULL
bottom	NULL
part	NULL
of	NULL
the	NULL
membrane	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
GST-IxBa-	NULL
(	NULL
1-53	NULL
)	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
its	NULL
phosphorylation	NULL
were	NULL
visualized	NULL
by	NULL
staining	NULL
with	NULL
Coomassie	NULL
Blue	NULL
and	NULL
autoradiography	NULL
,	NULL
respectively	NULL
.	NULL

Preparation	NULL
of	NULL
Recombinant	NULL
IxBa-The	NULL
IxBa	NULL
MADS	NULL
cDNA	NULL
(	NULL
85	NULL
)	NULL
plasmid	NULL
was	NULL
obtained	NULL
from	NULL
Chiron	NULL
and	NULL
used	NULL
as	NULL
a	NULL
template	NULL
for	NULL
subsequent	NULL
polymerase	NULL
chain	NULL
reaction	NULL
amplification	NULL
.	NULL

The	NULL
N-terminal	NULL
I	NULL
«	NULL
Ba	NULL
MADS	NULL
(	NULL
1-53	NULL
)	NULL
sequence	NULL
was	NULL
amplified	NULL
using	NULL
wild-type	NULL
primer	NULL
A	NULL
(	NULL
CGGGATC-CATGTTCCAGGCGGCCGAG	NULL
)	NULL
,	NULL
as	NULL
the	NULL
5	NULL
'	NULL
sense	NULL
primer	NULL
,	NULL
creating	NULL
a	NULL
BamHI	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
coding	NULL
sequence	NULL
,	NULL
and	NULL
wild-type	NULL
primer	NULL
B	NULL
(	NULL
GGAATTCCTCAGCGGATCTCCTGCAGCT	NULL
)	NULL
as	NULL
antisense	NULL
primer	NULL
,	NULL
creating	NULL
an	NULL
EcoRI	NULL
site	NULL
downstream	NULL
of	NULL
the	NULL
coding	NULL
sequence	NULL
.	NULL

A	NULL
double	NULL
SS2A/S86A	NULL
mutant	NULL
was	NULL
amplified	NULL
from	NULL
the	NULL
full-length	NULL
cDNA	NULL
using	NULL
polymerase	NULL
chain	NULL
reaction	NULL
primers	NULL
which	NULL
created	NULL
alanines	NULL
at	NULL
amino	NULL
acids	NULL
32	NULL
and	NULL
36	NULL
.	NULL

Following	NULL
digestion	NULL
with	NULL
BamHI	NULL
and	NULL
EcoRI	NULL
,	NULL
these	NULL
sequences	NULL
were	NULL
ligated	NULL
into	NULL
pGEX-KG	NULL
(	NULL
derived	NULL
from	NULL
pGEX-2T	NULL
from	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
transformed	NULL
into	NULL
Escherichia	NULL
coli	NULL
DHS5	NULL
@	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
grown	NULL
exponentially	NULL
,	NULL
and	NULL
after	NULL
60	NULL
min	NULL
of	NULL
stimulation	NULL
with	NULL
isopropylthiogalactopyranoside	NULL
(	NULL
Sig-ma	NULL
)	NULL
cells	NULL
were	NULL
lysed	NULL
.	NULL

Proteins	NULL
were	NULL
isolated	NULL
by	NULL
affinity	NULL
chromatography	NULL
on	NULL
glutathione-bonded	NULL
4	NULL
%	NULL
cross-linked	NULL
agarose	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
GST-I	NULL
«	NULL
Ba-	NULL
(	NULL
1-58	NULL
)	NULL
and	NULL
GST-I	NULL
«	NULL
Ba-	NULL
(	NULL
1-58	NULL
)	NULL
82A/86A	NULL
was	NULL
analyzed	NULL
with	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
22925	NULL
A	NULL
IgG	NULL
+	NULL
-	NULL
«	NULL
CD3	NULL
Ab	NULL
.	NULL

+	NULL
+	NULL
IxBo	NULL
IVK	NULL
|IxBa	NULL
wee	NULL
a-	NULL
a	NULL
>	NULL
IKK	NULL
IB	NULL
_	NULL
.___._-	NULL
cps3+t	NULL
Jurkat	NULL
IxBa	NULL
#	NULL
t	NULL
I	NULL
<	NULL
Bowt	NULL
IxBq324/36A	NULL
TNF	NULL
.	NULL

.	NULL

.	NULL

.	NULL

4	NULL
%	NULL
rx	NULL
PMA	NULL
.	NULL

.	NULL

%	NULL
4	NULL
%	NULL
>	NULL
>	NULL
!	NULL

Aca	NULL
IONQ	NULL
-	NULL
+	NULL
>	NULL
>	NULL
+	NULL
>	NULL
mo	NULL
#	NULL
0+	NULL
#	NULL
o	NULL
>	NULL
€00	NULL
%	NULL
0+	NULL
0	NULL
#	NULL
o	NULL
>	NULL
IcBa	NULL
*°P	NULL
-	NULL
«	NULL
»	NULL
dD	NULL
«	NULL
w	NULL
»	NULL
IVK	NULL
|IxBa	NULL
wee	NULL
wus	NULL
muss	NULL
cues	NULL
se	NULL
~	NULL
Seep	NULL
wee	NULL
Sunt	NULL
cust	NULL
|	NULL
Whe	NULL
wees	NULL
cme	NULL
came	NULL
wost	NULL
IKK	NULL
IB	NULL
-	NULL
(	NULL
sms	NULL
s	NULL
de	NULL
_	NULL
ue	NULL
mans	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
in	NULL
vivo	NULL
|	NULL
IB	NULL
eet	NULL
«	NULL
mme	NULL
suus	NULL
UOS	NULL
...	NULL
o	NULL
wee	NULL
we	NULL
sume	NULL
mee	NULL
*~	NULL
1°	NULL
2	NULL
%	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
IgG	NULL
Ase	NULL
istr	NULL
Sat	NULL
TNF	NULL
Ashes	NULL
!	NULL

»	NULL
Asst	NULL
PMA	NULL
IONO	NULL
IxBa	NULL
*2P	NULL
bcen	NULL
cue	NULL
«	NULL
wens	NULL
-	NULL
aoa	NULL
IVK	NULL
|	NULL
IxBa	NULL
wore	NULL
wee	NULL
wees	NULL
cuse	NULL
cue	NULL
.	NULL

Gime	NULL
meum	NULL
mee	NULL
ues	NULL
emm	NULL
meet	NULL
IKK	NULL
IB	NULL
wom	NULL
ha	NULL
mem	NULL
tue	NULL
me	NULL
l	NULL
muses	NULL
must	NULL
meee	NULL
cuca	NULL
oot	NULL
10	NULL
2	NULL
3	NULL
4	NULL
5	NULL
60	NULL
7	NULL
B8	NULL
9	NULL
10	NULL
11	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

PKC-	NULL
and	NULL
Ca	NULL
``	NULL
+*-dependent	NULL
pathways	NULL
are	NULL
required	NULL
for	NULL
the	NULL
IKK	NULL
complex	NULL
activation	NULL
.	NULL

A	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
following	NULL
TCR/CD3	NULL
cross-linking	NULL
is	NULL
calcineurin-dependent	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°cells	NULL
per	NULL
sample	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
3	NULL
pg/ml	NULL
anti-CD3	NULL
(	NULL
Zanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
or	NULL
isotype	NULL
control	NULL
IgG	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
antibody	NULL
for	NULL
45	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
media	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
cross-linked	NULL
on	NULL
goat	NULL
anti-mouse-coated	NULL
plates	NULL
for	NULL
20	NULL
min	NULL
at	NULL
387	NULL
°C	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
20	NULL
ng/ml	NULL
FK506	NULL
before	NULL
incubation	NULL
with	NULL
anti-CD3	NULL
antibodies	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
.	NULL

IKK	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
(	NULL
IVK	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
,	NULL
``	NULL
using	NULL
GST-IxBa	NULL
(	NULL
1-53	NULL
amino	NULL
acids	NULL
)	NULL
as	NULL
substrate	NULL
(	NULL
IxBa	NULL
**P	NULL
)	NULL
.	NULL

Coomassie	NULL
staining	NULL
of	NULL
the	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
containing	NULL
the	NULL
IVK	NULL
(	NULL
IxBa	NULL
)	NULL
and	NULL
immunoblotting	NULL
(	NULL
IB	NULL
)	NULL
for	NULL
IKKa	NULL
(	NULL
IKKa	NULL
IB	NULL
)	NULL
were	NULL
performed	NULL
.	NULL

B	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
synergize	NULL
to	NULL
activate	NULL
IKK	NULL
in	NULL
Jurkat	NULL
and	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Primary	NULL
CD38	NULL
(	NULL
Zanes	NULL
1-5	NULL
)	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Zanes	NULL
6-15	NULL
)	NULL
were	NULL
stimulated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
for	NULL
8	NULL
min	NULL
with	NULL
ionomycin	NULL
(	NULL
JONO	NULL
)	NULL
,	NULL
PMA	NULL
,	NULL
or	NULL
TNF	NULL
.	NULL

For	NULL
CD3	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
PMA	NULL
was	NULL
used	NULL
at	NULL
2.5	NULL
ng/ml	NULL
,	NULL
ionomycin	NULL
at	NULL
0.7	NULL
ug/ml	NULL
for	NULL
8	NULL
min	NULL
,	NULL
and	NULL
TNF	NULL
«	NULL
at	NULL
10	NULL
ng/ml	NULL
for	NULL
4	NULL
min	NULL
;	NULL
for	NULL
Jurkat	NULL
T	NULL
cell	NULL
stimulation	NULL
PMA	NULL
was	NULL
used	NULL
at	NULL
20	NULL
ng/ml	NULL
,	NULL
ionomycin	NULL
at	NULL
3.5	NULL
ug/ml	NULL
for	NULL
8	NULL
min	NULL
,	NULL
and	NULL
TNF-a	NULL
at	NULL
10	NULL
ng/ml	NULL
for	NULL
8	NULL
min	NULL
.	NULL

IKK	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
an	NULL
IVK	NULL
using	NULL
GST-I	NULL
«	NULL
kBa-	NULL
(	NULL
1-53	NULL
)	NULL
as	NULL
substrate	NULL
(	NULL
IxBa	NULL
*°P	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
IKK	NULL
kinase	NULL
activity	NULL
toward	NULL
to	NULL
Ser-82/Ser-86	NULL
was	NULL
demonstrated	NULL
by	NULL
using	NULL
GST-I	NULL
«	NULL
Ba	NULL
(	NULL
1-53	NULL
amino	NULL
acids	NULL
)	NULL
with	NULL
substituted	NULL
serines	NULL
for	NULL
alanines	NULL
(	NULL
IxB	NULL
&	NULL
``	NULL
``	NULL
``	NULL
,	NULL
lanes	NULL
11-15	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
the	NULL
level	NULL
of	NULL
endogenous	NULL
IxBa	NULL
from	NULL
the	NULL
same	NULL
cell	NULL
extracts	NULL
were	NULL
detected	NULL
by	NULL
immunoblotting	NULL
with	NULL
anti-IxBa	NULL
antibodies	NULL
(	NULL
IxBa	NULL
IB	NULL
in	NULL
vivo	NULL
)	NULL
.	NULL

C	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
anes	NULL
1-5	NULL
)	NULL
or	NULL
pretreated	NULL
with	NULL
4	NULL
ug/ml	NULL
neutralizing	NULL
anti-TNF	NULL
antibody	NULL
(	NULL
lanes	NULL
6-8	NULL
)	NULL
or	NULL
with	NULL
4	NULL
ug/ml	NULL
isotype	NULL
control	NULL
IgG	NULL
antibody	NULL
(	NULL
Zanes	NULL
9-11	NULL
)	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
stimulation	NULL
.	NULL

Efficiency	NULL
of	NULL
the	NULL
neutralizing	NULL
anti-TNF	NULL
antibody	NULL
was	NULL
demonstrated	NULL
by	NULL
using	NULL
the	NULL
mixture	NULL
of	NULL
recombinant	NULL
TNF	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
with	NULL
neutralizing	NULL
anti-TNF	NULL
antibody	NULL
(	NULL
4	NULL
ug/ml	NULL
)	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
before	NULL
stimulation	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
.	NULL

IKK	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
IVK	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
substrate	NULL
and	NULL
the	NULL
immunoprecipitated	NULL
kinase	NULL
complex	NULL
were	NULL
present	NULL
in	NULL
the	NULL
assay	NULL
confirmed	NULL
by	NULL
Coomassie	NULL
staining	NULL
of	NULL
the	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
containing	NULL
the	NULL
IVK	NULL
(	NULL
/xBa	NULL
)	NULL
,	NULL
and	NULL
immunoblotting	NULL
(	NULL
ZB	NULL
)	NULL
for	NULL
IKKa	NULL
(	NULL
IKKa	NULL
IB	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

10	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
subsequent	NULL
Coomassie	NULL
Blue	NULL
staining	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
both	NULL
proteins	NULL
was	NULL
greater	NULL
than	NULL
90	NULL
%	NULL
.	NULL

Gene	NULL
Transfection	NULL
and	NULL
Reporter	NULL
Assays-FuGENEG	NULL
was	NULL
used	NULL
to	NULL
express	NULL
plasmids	NULL
transiently	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
8	NULL
pl	NULL
of	NULL
FuGENE6	NULL
(	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
92	NULL
pl	NULL
of	NULL
plain	NULL
RPMI	NULL
1640	NULL
media	NULL
and	NULL
incubated	NULL
for	NULL
5	NULL
min	NULL
.	NULL

FuGENEG/RPMI	NULL
1640	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
sterile	NULL
tube	NULL
containing	NULL
0.4	NULL
ug	NULL
of	NULL
<	NULL
B-lue	NULL
reporter	NULL
plasmid	NULL
,	NULL
0.6	NULL
ug	NULL
of	NULL
pREP4/CAT	NULL
,	NULL
and	NULL
0-1	NULL
ug	NULL
of	NULL
a	NULL
plasmid	NULL
of	NULL
interest	NULL
(	NULL
total	NULL
is	NULL
2	NULL
ug	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
DNA/sFuGENE6	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
1	NULL
X	NULL
10°	NULL
log	NULL
phase	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
plasmids	NULL
and	NULL
grown	NULL
for	NULL
40	NULL
h.	NULL
Cells	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
8.5	NULL
ug/ml	NULL
)	NULL
,	NULL
TNF-a	NULL
(	NULL
10	NULL
ng/m1	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
and	NULL
ionomycin	NULL
together	NULL
.	NULL

After	NULL
stimulation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
lysed	NULL
with	NULL
210	NULL
ul	NULL
lysis	NULL
solution	NULL
(	NULL
100	NULL
mM	NULL
K	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
pH	NULL
7.8	NULL
;	NULL
0.2	NULL
%	NULL
Triton	NULL
X-100	NULL
;	NULL
5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
(	NULL
100	NULL
pl	NULL
)	NULL
of	NULL
extract	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
and	NULL
CAT	NULL
expression	NULL
.	NULL

CAT	NULL
expression	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
Roche	NULL
Molecular	NULL
Biochemicals	NULL
CAT	NULL
en-	NULL
zyme-linked	NULL
immunosorbent	NULL
assay	NULL
kit	NULL
using	NULL
the	NULL
manufacturer	NULL
's	NULL
proto-col.	NULL
Luciferase	NULL
activity	NULL
was	NULL
assayed	NULL
using	NULL
the	NULL
Promega	NULL
Luciferin	NULL
reagent	NULL
and	NULL
a	NULL
Berthold	NULL
Lumat	NULL
.	NULL

Luciferase	NULL
activity	NULL
is	NULL
normalized	NULL
to	NULL
CAT	NULL
expression	NULL
.	NULL

All	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

RESULTS	NULL
PKC-	NULL
and	NULL
Ca*	NULL
``	NULL
*-dependent	NULL
Pathways	NULL
Synergize	NULL
to	NULL
Activate	NULL
the	NULL
IKK	NULL
Complex	NULL
in	NULL
T	NULL
Cells-Cross-linking	NULL
of	NULL
the	NULL
TCRWCD3	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
PKC-	NULL
and	NULL
Ca**-dependent	NULL
pathways	NULL
that	NULL
synergize	NULL
in	NULL
T	NULL
cells	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
targeting	NULL
the	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
its	NULL
inhibitor	NULL
,	NULL
I	NULL
«	NULL
xBa	NULL
(	NULL
11	NULL
,	NULL
31	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
TCR	NULL
cross-linking	NULL
can	NULL
lead	NULL
to	NULL
IKK	NULL
activation	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
immunoprecipitated	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
activated	NULL
or	NULL
not	NULL
following	NULL
TCR	NULL
cross-linking	NULL
.	NULL

Cross-linking	NULL
of	NULL
the	NULL
TCR	NULL
with	NULL
anti-CD3	NULL
but	NULL
not	NULL
IgG	NULL
antibodies	NULL
results	NULL
in	NULL
a	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
22926	NULL
moderate	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
2nd	NULL
lane	NULL
)	NULL
,	NULL
which	NULL
is	NULL
inhibited	NULL
by	NULL
pretreatment	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
calcineurin-specific	NULL
inhibitor	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
and	NULL
based	NULL
on	NULL
previous	NULL
studies	NULL
from	NULL
our	NULL
group	NULL
(	NULL
11	NULL
,	NULL
31	NULL
)	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
calcineurin	NULL
participates	NULL
in	NULL
the	NULL
TCR/	NULL
CD3-initiated	NULL
signal	NULL
transduction	NULL
pathway	NULL
that	NULL
leads	NULL
to	NULL
IKK	NULL
activation	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
and	NULL
calcineurin	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
,	NULL
an	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
using	NULL
IKK	NULL
complex	NULL
immunoprecipitates	NULL
from	NULL
resting	NULL
freshly	NULL
isolated	NULL
peripheral	NULL
human	NULL
T	NULL
lymphocytes	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
or	NULL
were	NULL
not	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
,	NULL
PMA	NULL
,	NULL
or	NULL
their	NULL
combination	NULL
.	NULL

Ionomycin	NULL
stimulation	NULL
of	NULL
CD3¢*	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
IKK	NULL
complex	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
,	NULL
whereas	NULL
PMA	NULL
induces	NULL
a	NULL
moderate	NULL
IxBa	NULL
kinase	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
stimulation	NULL
of	NULL
CD3	NULL
*	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
increased	NULL
the	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
beyond	NULL
that	NULL
observed	NULL
in	NULL
PMA-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
.	NULL

When	NULL
TNF	NULL
treatment	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
of	NULL
IKK	NULL
activation	NULL
(	NULL
24	NULL
)	NULL
,	NULL
it	NULL
was	NULL
observed	NULL
that	NULL
the	NULL
degree	NULL
of	NULL
TNF	NULL
activation	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
PMA	NULL
but	NULL
significantly	NULL
lower	NULL
than	NULL
that	NULL
achieved	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
was	NULL
specific	NULL
for	NULL
Ser-32/Ser-36	NULL
,	NULL
as	NULL
it	NULL
was	NULL
not	NULL
observed	NULL
when	NULL
an	NULL
IxBa	NULL
substrate	NULL
in	NULL
which	NULL
both	NULL
serines	NULL
were	NULL
substituted	NULL
with	NULL
alanines	NULL
was	NULL
used	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
11-15	NULL
)	NULL
.	NULL

Equal	NULL
amount	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
substrate	NULL
present	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
IxkBa	NULL
)	NULL
or	NULL
the	NULL
amount	NULL
of	NULL
IKK	NULL
complex	NULL
immunoprecipitated	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
lanes	NULL
I-5	NULL
)	NULL
confirmed	NULL
that	NULL
the	NULL
increased	NULL
in	NULL
vitro	NULL
phosphorylation	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
is	NULL
a	NULL
function	NULL
of	NULL
enhanced	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
IKK	NULL
complex	NULL
was	NULL
immunoprecipitated	NULL
with	NULL
additional	NULL
anti-IKKa	NULL
or	NULL
IKK	NULL
$	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Raf-1	NULL
immunoprecipitates	NULL
of	NULL
cell	NULL
lysates	NULL
from	NULL
PMA	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
or	NULL
TNF	NULL
-stimulated	NULL
cells	NULL
did	NULL
not	NULL
result	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
at	NULL
Ser-32/Ser-36	NULL
,	NULL
despite	NULL
evidence	NULL
of	NULL
Raf-1	NULL
activation	NULL
following	NULL
PMA	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
qualitative	NULL
differences	NULL
in	NULL
the	NULL
IKK	NULL
activation	NULL
triggered	NULL
by	NULL
PMA	NULL
or	NULL
PMA	NULL
and	NULL
ionomycin	NULL
correlated	NULL
with	NULL
the	NULL
in	NULL
vivo	NULL
IxBa	NULL
hyperphosphorylation	NULL
,	NULL
the	NULL
same	NULL
cell	NULL
lysates	NULL
used	NULL
for	NULL
immunoprecipitation	NULL
of	NULL
cell	NULL
kinases	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
immunoblotted	NULL
for	NULL
endogenous	NULL
IxBa	NULL
using	NULL
anti-IxBa-specific	NULL
antibodies	NULL
.	NULL

Hyperphosphorylation	NULL
of	NULL
IxBa	NULL
,	NULL
determined	NULL
by	NULL
the	NULL
slower	NULL
migrating	NULL
form	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
,	NULL
was	NULL
mainly	NULL
observed	NULL
in	NULL
the	NULL
PMA-	NULL
and	NULL
ionomycin-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
IxBa	NULL
IB	NULL
in	NULL
vivo	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
establishes	NULL
a	NULL
direct	NULL
correlation	NULL
between	NULL
the	NULL
qualitative	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
by	NULL
PKC-	NULL
and	NULL
Ca**-dependent	NULL
pathways	NULL
and	NULL
IxBa	NULL
hyperphosphorylation	NULL
in	NULL
vivo	NULL
.	NULL

To	NULL
demonstrate	NULL
that	NULL
the	NULL
observed	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
is	NULL
the	NULL
direct	NULL
effect	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
co-stimulation	NULL
,	NULL
and	NULL
not	NULL
due	NULL
to	NULL
their	NULL
secondary	NULL
induction	NULL
of	NULL
TNF	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
from	NULL
PMA-	NULL
and	NULL
ionomycin-treated	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
not	NULL
of	NULL
neutralizing	NULL
anti-TNF	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Pretreatment	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
such	NULL
antibodies	NULL
abrogates	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
by	NULL
recombinant	NULL
TNF	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
but	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
IKK	NULL
complex	NULL
activation	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
and	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
neutralizing	NULL
anti-TNF	NULL
antibodies	NULL
was	NULL
confirmed	NULL
by	NULL
their	NULL
preincubation	NULL
with	NULL
recombinant	NULL
TNF	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
by	NULL
using	NULL
IgG	NULL
isotype	NULL
antibodies	NULL
as	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
lanes	NULL
9-11	NULL
)	NULL
.	NULL

p90	NULL
**	NULL
Is	NULL
Synergistically	NULL
Activated	NULL
by	NULL
PKC-	NULL
and	NULL
Ca	NULL
``	NULL
*-de-pendent	NULL
Pathways-The	NULL
mitogen-activated	NULL
p90	NULL
**	NULL
phosphoryl-	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
A	NULL
Jurkat	NULL
FK	NULL
506	NULL
_	NULL
-o	NULL
og	NULL
%	NULL
PMA	NULL
so	NULL
ge	NULL
Go	NULL
go	NULL
#	NULL
IONO	NULL
+	NULL
+	NULL
IKK	NULL
IP	NULL
«	NULL
an	NULL
at	NULL
pQO	NULL
's	NULL
``	NULL
IP	NULL
wore	NULL
sume	NULL
muss	NULL
in	NULL
vivo	NULL
|	NULL
IkBo	NULL
.	NULL

IB	NULL
e*	NULL
=	NULL
--	NULL
«	NULL
--	NULL
-	NULL
=a	NULL
--	NULL
10	NULL
20	NULL
3	NULL
4	NULL
5	NULL
B	NULL
Cp3+	NULL
FK	NULL
506	NULL
t	NULL
ot	NULL
ot	NULL
to	NULL
o*	NULL
+	NULL
+	NULL
#	NULL
+	NULL
+	NULL
#	NULL
TNF	NULL
£0	NULL
stl	NULL
on	NULL
mu	NULL
=	NULL
®	NULL
+	NULL
PMA	NULL
=	NULL
.	NULL

o	NULL
>	NULL
4	NULL
4+	NULL
o-	NULL
>	NULL
o	NULL
8	NULL
0	NULL
#	NULL
0	NULL
#	NULL
o	NULL
>	NULL
ONG	NULL
.	NULL

oy	NULL
.	NULL

os	NULL
n	NULL
£	NULL
.	NULL

og	NULL
IKK	NULL
IP	NULL
«	NULL
«	NULL
@	NULL
<	NULL
ilh	NULL
-	NULL
wes	NULL
quem	NULL
cue	NULL
psorslqp	NULL
wc	NULL
suo	NULL
.	NULL

In	NULL
vivo	NULL
|	NULL
IxBa	NULL
.	NULL

IB	NULL
==	NULL
wee	NULL
su	NULL
10	NULL
20	NULL
3	NULL
4	NULL
5	NULL
60	NULL
7	NULL
8	NULL
90	NULL
10	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Calcineurin	NULL
mediates	NULL
synergistic	NULL
IKK	NULL
activation	NULL
,	NULL
but	NULL
not	NULL
p90**	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
with	NULL
20	NULL
ng/ml	NULL
specific	NULL
calcineurin	NULL
inhibitor	NULL
FK506	NULL
1	NULL
h	NULL
before	NULL
stimulation	NULL
with	NULL
PMA	NULL
and/or	NULL
ionomycin	NULL
.	NULL

Immunoprecipitated	NULL
p90'**	NULL
(	NULL
p90	NULL
``	NULL
**	NULL
IP	NULL
)	NULL
and	NULL
the	NULL
IKK	NULL
complex	NULL
(	NULL
IKKa	NULL
IP	NULL
)	NULL
were	NULL
analyzed	NULL
in	NULL
IVK	NULL
.	NULL

IVK	NULL
and	NULL
IB	NULL
are	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

B	NULL
,	NULL
same	NULL
as	NULL
A	NULL
except	NULL
that	NULL
primary	NULL
CD3¢*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
.	NULL

Lymphocytes	NULL
were	NULL
pretreated	NULL
with	NULL
100	NULL
ng/ml	NULL
FK506	NULL
1	NULL
h	NULL
before	NULL
stimulation	NULL
.	NULL

ates	NULL
IxBa	NULL
at	NULL
Ser-32	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
questioned	NULL
whether	NULL
it	NULL
directly	NULL
results	NULL
in	NULL
IxBa	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
in	NULL
vivo	NULL
(	NULL
20-23	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Because	NULL
p90'**	NULL
is	NULL
a	NULL
second	NULL
messenger	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
PKC	NULL
(	NULL
87	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
Ca**-dependent	NULL
pathways	NULL
synergistically	NULL
activated	NULL
the	NULL
presumed	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
p90'®*	NULL
that	NULL
would	NULL
be	NULL
induced	NULL
following	NULL
PKC	NULL
stimulation	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
and	NULL
freshly	NULL
isolated	NULL
peripheral	NULL
blood	NULL
CD3	NULL
*	NULL
T	NULL
lymphocytes	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and/or	NULL
ionomycin	NULL
,	NULL
and	NULL
p90'**	NULL
and	NULL
IKK	NULL
complexes	NULL
were	NULL
subsequently	NULL
immunoprecipitated	NULL
and	NULL
analyzed	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
phosphorylate	NULL
IxBa	NULL
at	NULL
Ser-32/Ser-36	NULL
.	NULL

In	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
PMA	NULL
alone	NULL
significantly	NULL
induces	NULL
the	NULL
p90'**	NULL
IxBa	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
IP	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
only	NULL
weakly	NULL
increased	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
p90'**	NULL
beyond	NULL
that	NULL
induced	NULL
by	NULL
the	NULL
stimulation	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
p90	NULL
``	NULL
**	NULL
IP	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
suggesting	NULL
that	NULL
at	NULL
this	NULL
concentration	NULL
of	NULL
PMA	NULL
,	NULL
p90'®*	NULL
is	NULL
already	NULL
fully	NULL
activated	NULL
.	NULL

In	NULL
primary	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
in	NULL
contrast	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
strong	NULL
synergistic	NULL
activation	NULL
of	NULL
p90	NULL
``	NULL
toward	NULL
the	NULL
IxBa	NULL
substrate	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
p90'®*	NULL
IP	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
stimulation	NULL
by	NULL
ionomycin	NULL
alone	NULL
does	NULL
not	NULL
induce	NULL
p90	NULL
``	NULL
®*	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
p90	NULL
’	NULL
Sk	NULL
IP	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Calcineurin	NULL
Is	NULL
Required	NULL
for	NULL
Synergistic	NULL
Activation	NULL
of	NULL
the	NULL
IKK	NULL
Complex	NULL
but	NULL
Not	NULL
p90®*	NULL
in	NULL
T	NULL
Lymphocytes-The	NULL
role	NULL
of	NULL
Ca**-dependent	NULL
signaling	NULL
and	NULL
of	NULL
calcineurin	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
and	NULL
p90'**	NULL
kinase	NULL
activity	NULL
was	NULL
investigated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
calcineurin-specific	NULL
inhibitor	NULL
FK506	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
and	NULL
freshly	NULL
isolated	NULL
T	NULL
lymphocytes	NULL
were	NULL
pretreated	NULL
with	NULL
FK506	NULL
for	NULL
1	NULL
h	NULL
followed	NULL
by	NULL
their	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
their	NULL
combination	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
FK506	NULL
reverses	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
in	NULL
both	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
IKK	NULL
IP	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
and	NULL
in	NULL
primary	NULL
CD3¢	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
IKK	NULL
IP	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
,	NULL
9	NULL
)	NULL
and	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
p90'**	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
p90	NULL
**	NULL
IP	NULL
,	NULL
lanes	NULL
2-5	NULL
;	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
p90	NULL
**	NULL
IP	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
and	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

The	NULL
reduction	NULL
of	NULL
IKK	NULL
kinase	NULL
activity	NULL
in	NULL
vitro	NULL
by	NULL
FK506	NULL
correlates	NULL
with	NULL
the	NULL
decrease	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
IxBa	NULL
hyperphosphorylation	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
in	NULL
vivo	NULL
IxBa	NULL
IB	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
;	NULL
and	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
in	NULL
vivo	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
22927	NULL
A	NULL
pao	NULL
's	NULL
IP	NULL
IKK	NULL
IP	NULL
IsBq324/36A	NULL
IxBo	NULL
#	NULL
*	NULL
rol	NULL
gH	NULL
Cle	NULL
PMA	NULL
-	NULL
0	NULL
+	NULL
4+	NULL
-o	NULL
+	NULL
+	NULL
+	NULL
)	NULL
|	NULL
#	NULL
isk	NULL
-~	NULL
+	NULL
#	NULL
elle	NULL
IxBa	NULL
*P	NULL
«	NULL
«	NULL
»	NULL
cm	NULL
»	NULL
e	NULL
«	NULL
a	NULL
»	NULL
>	NULL
kie	NULL
IVK	NULL
|IxBa	NULL
M	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
Pgnrsk|B-_—-____	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

PD	NULL
098059	NULL
inhibits	NULL
PMA/	NULL
ionomycin-induced	NULL
p90'**	NULL
activation	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
IxBa	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
in	NULL
vivo	NULL
.	NULL

A	NULL
,	NULL
Jur-	NULL
B	NULL
kat	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
for	NULL
20	NULL
min	NULL
with	NULL
30	NULL
um	NULL
PD	NULL
098059	NULL
(	NULL
PD	NULL
)	NULL
and	NULL
subsequently	NULL
stimulated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
with	NULL
PMA	NULL
and/or	NULL
ionomycin	NULL
.	NULL

Immunoprecipitates	NULL
of	NULL
p90'*	NULL
IP	NULL
)	NULL
or	NULL
of	NULL
IKKa	NULL
(	NULL
IKK	NULL
IP	NULL
)	NULL
were	NULL
analyzed	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
(	NULL
IVK	NULL
)	NULL
.	NULL

IVK	NULL
and	NULL
IB	NULL
are	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

B	NULL
,	NULL
same	NULL
as	NULL
in	NULL
A	NULL
except	NULL
that	NULL
primary	NULL
CD3*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
.	NULL

C	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
«	NULL
B-luc-	NULL
(	NULL
0.4	NULL
ug	NULL
)	NULL
and	NULL
REPA/CAT	NULL
(	NULL
0.6	NULL
ug	NULL
)	NULL
reporter	NULL
plasmids	NULL
.	NULL

Forty	NULL
hours	NULL
later	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
30	NULL
uM	NULL
inhibitor	NULL
PD	NULL
098059	NULL
for	NULL
20	NULL
min	NULL
and	NULL
then	NULL
stimulated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
with	NULL
PMA	NULL
and/or	NULL
ionomycin	NULL
for	NULL
4	NULL
h.	NULL
Equal	NULL
amounts	NULL
(	NULL
100	NULL
pl	NULL
)	NULL
of	NULL
extracts	NULL
were	NULL
assayed	NULL
C	NULL
for	NULL
luciferase	NULL
and	NULL
CAT	NULL
expression	NULL
.	NULL

Luciferase	NULL
activity	NULL
is	NULL
normalized	NULL
to	NULL
CAT	NULL
expression	NULL
(	NULL
relative	NULL
luciferase	NULL
activity	NULL
)	NULL
.	NULL

All	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

IxBa	NULL
IB	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
FK506	NULL
as	NULL
an	NULL
inhibitor	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor-initiated	NULL
signaling	NULL
leading	NULL
to	NULL
IKK	NULL
activation	NULL
was	NULL
tested	NULL
in	NULL
the	NULL
TNF-mediated	NULL
IKK	NULL
activation	NULL
and	NULL
in	NULL
vivo	NULL
I	NULL
«	NULL
xBa	NULL
phosphorylation	NULL
.	NULL

TNF-induced	NULL
IKK	NULL
activation	NULL
and	NULL
IxBa-induced	NULL
hyperphosphorylation	NULL
in	NULL
vivo	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
pretreatment	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
in	NULL
vivo	NULL
IxBa	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Altogether	NULL
,	NULL
these	NULL
results	NULL
demonstrate	NULL
a	NULL
direct	NULL
correlation	NULL
between	NULL
the	NULL
degree	NULL
of	NULL
IKK	NULL
activation	NULL
and	NULL
the	NULL
in	NULL
vivo	NULL
IxBa	NULL
hyperphosphorylation	NULL
.	NULL

Moreover	NULL
,	NULL
they	NULL
point	NULL
to	NULL
the	NULL
necessary	NULL
role	NULL
of	NULL
calcineurin	NULL
in	NULL
mediating	NULL
the	NULL
hyperphosphorylation	NULL
of	NULL
IxBa	NULL
by	NULL
IKK	NULL
following	NULL
the	NULL
activation	NULL
of	NULL
PKC-	NULL
and	NULL
Ca*	NULL
``	NULL
*-dependent	NULL
signaling	NULL
that	NULL
is	NULL
triggered	NULL
by	NULL
TCR	NULL
cross-linking	NULL
.	NULL

The	NULL
IKK	NULL
Complex	NULL
and	NULL
Not	NULL
p90®*	NULL
Controls	NULL
Inducible	NULL
IxBa	NULL
Phosphorylation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
Activation	NULL
in	NULL
T	NULL
Cells-To	NULL
evaluate	NULL
the	NULL
in	NULL
vivo	NULL
role	NULL
of	NULL
p90'**	NULL
as	NULL
an	NULL
IxBa	NULL
kinase	NULL
involved	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
we	NULL
used	NULL
the	NULL
specific	NULL
MEK-1	NULL
inhibitor	NULL
PD	NULL
098059	NULL
(	NULL
PD	NULL
)	NULL
(	NULL
39	NULL
)	NULL
to	NULL
block	NULL
p90'*	NULL
activation	NULL
(	NULL
40	NULL
)	NULL
.	NULL

In	NULL
Jurkat	NULL
T	NULL
cells	NULL
a	NULL
strong	NULL
activation	NULL
of	NULL
p90	NULL
“	NULL
,	NULL
B	NULL
IxBa	NULL
activity	NULL
by	NULL
PMA	NULL
was	NULL
reversed	NULL
by	NULL
PD	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
IxBa	NULL
*°P	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
only	NULL
moderately	NULL
increased	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
p90	NULL
``	NULL
**	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
IxBa	NULL
*P	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
PD	NULL
did	NULL
not	NULL
completely	NULL
eliminate	NULL
the	NULL
PMA-	NULL
and	NULL
ionomycin-induced	NULL
activation	NULL
of	NULL
the	NULL
p90	NULL
**	NULL
IxBa	NULL
kinase	NULL
activity	NULL
,	NULL
allowing	NULL
the	NULL
detection	NULL
of	NULL
a	NULL
degree	NULL
of	NULL
synergy	NULL
when	NULL
compared	NULL
with	NULL
PMA	NULL
and	NULL
PD-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
IxBa	NULL
*P	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

This	NULL
residual	NULL
effect	NULL
was	NULL
completely	NULL
1	NULL
2	NULL
%	NULL
4	NULL
5	NULL
6	NULL
7T	NULL
8	NULL
PD	NULL
ells	NULL
es	NULL
#	NULL
111	NULL
TNF	NULL
-	NULL
>	NULL
-	NULL
SMal	NULL
x	NULL
alee	NULL
21x	NULL
lnm	NULL
dnl	NULL
:	NULL
10NG	NULL
|	NULL
€	NULL
+	NULL
!	NULL

!	NULL

!	NULL

eee	NULL
IxBa	NULL
*P	NULL
bed	NULL
pgorsk	NULL
IP|	NULL
IBa	NULL
p9o	NULL
``	NULL
s	NULL
IB	NULL
IKK	NULL
IP	NULL
IxBa	NULL
P	NULL
amp	NULL
~	NULL
«	NULL
ip	NULL
~~	NULL
in	NULL
vivo	NULL
IxBa	NULL
IB	NULL
-	NULL
#	NULL
#	NULL
#	NULL
*	NULL
«	NULL
sae	NULL
suse	NULL
-~	NULL
Seem	NULL
tue	NULL
uous	NULL
ECT	NULL
_	NULL
>	NULL
7	NULL
B8	NULL
9	NULL
10	NULL
Relative	NULL
luciferase	NULL
activity	NULL
blocked	NULL
by	NULL
PD	NULL
treatment	NULL
for	NULL
a	NULL
longer	NULL
time	NULL
(	NULL
1	NULL
h	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
MEK-1	NULL
mediates	NULL
both	NULL
PKC-	NULL
and	NULL
Ca**-dependent	NULL
signaling	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
PD	NULL
as	NULL
a	NULL
p90	NULL
``	NULL
®*	NULL
inhibitor	NULL
in	NULL
this	NULL
model	NULL
was	NULL
further	NULL
evaluated	NULL
by	NULL
measuring	NULL
its	NULL
inhibitory	NULL
activity	NULL
on	NULL
the	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
from	NULL
the	NULL
same	NULL
lysates	NULL
.	NULL

The	NULL
synergy	NULL
between	NULL
PKC-	NULL
and	NULL
Ca**-dependent	NULL
pathways	NULL
that	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
as	NULL
an	NULL
IxBa	NULL
kinase	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
was	NULL
minimally	NULL
modified	NULL
by	NULL
PD	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lane	NULL
14	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
PD	NULL
inhibits	NULL
p90'**	NULL
activation	NULL
but	NULL
not	NULL
the	NULL
IKK	NULL
complex	NULL
.	NULL

In	NULL
primary	NULL
CD3¢	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
p90'®*	NULL
toward	NULL
IxBa	NULL
substrate	NULL
was	NULL
synergistically	NULL
increased	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
IxBa	NULL
°°P	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
an	NULL
effect	NULL
that	NULL
was	NULL
reversed	NULL
when	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PD	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
p90'**	NULL
kinase	NULL
activity	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
IxBa	NULL
substrate	NULL
present	NULL
in	NULL
the	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
or	NULL
the	NULL
amount	NULL
of	NULL
p90'®*	NULL
immunoprecipitated	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
p90	NULL
®*	NULL
IP	NULL
,	NULL
IxBa	NULL
,	NULL
and	NULL
p90	NULL
**	NULL
IB	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
TNF	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
p90	NULL
**	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
IxBa	NULL
*°P	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
PD	NULL
was	NULL
once	NULL
again	NULL
verified	NULL
in	NULL
primary	NULL
CD3*	NULL
T	NULL
cells	NULL
by	NULL
determining	NULL
whether	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
activity	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
was	NULL
PD-insensitive	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
(	NULL
IKK	NULL
IP	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
resulted	NULL
in	NULL
the	NULL
synergistic	NULL
activity	NULL
of	NULL
IKK	NULL
that	NULL
was	NULL
not	NULL
modified	NULL
by	NULL
pretreatment	NULL
of	NULL
cells	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
22928	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
A	NULL
amii	NULL
.	NULL

fll	NULL
ill	NULL
al	NULL
all	NULL
lloc	NULL
+/*	NULL
!	NULL

se	NULL
)	NULL
Aite	NULL
,	NULL
itt	NULL
t	NULL
>	NULL
PMA	NULL
-	NULL
+	NULL
+	NULL
>	NULL
AMIE	NULL
uh	NULL
ONO	NULL
®	NULL
-	NULL
>	NULL
=	NULL
+	NULL
>	NULL
aloe	NULL
M	NULL
z	NULL
|	NULL
|P	NULL
IxBa	NULL
IVK	NULL
v0	NULL
C	NULL
#	NULL
:	NULL
dee	NULL
pi	NULL
Siwa	NULL
in	NULL
vivo	NULL
-	NULL
IkBa	NULL
IB	NULL
``	NULL
*	NULL
==	NULL
--	NULL
-	NULL
suus	NULL
wee	NULL
cme	NULL
mugs	NULL
some	NULL
mmm	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Conventional	NULL
PKC	NULL
isoforms	NULL
1°	NULL
O2	NULL
3	NULL
%	NULL
5	NULL
6	NULL
T	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
are	NULL
required	NULL
for	NULL
IKK	NULL
and	NULL
NF-KB	NULL
acti-	NULL
B	NULL
gr	NULL
~	NULL
Anoto	NULL
?	NULL

slits	NULL
oal	NULL
vation	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
Gb	NULL
-	NULL
Ae	NULL
M	NULL
M	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
with	NULL
2	NULL
uM	NULL
GF	NULL
and	NULL
2	NULL
pM	NULL
G6	NULL
TNF	NULL
-	NULL
|	NULL
|	NULL
|	NULL
4	NULL
II	NULL
Il	NULL
I	NULL
1	NULL
+	NULL
I	NULL
U	NULL
Ul	NULL
+	NULL
6976	NULL
(	NULL
GS	NULL
)	NULL
for	NULL
15	NULL
min	NULL
before	NULL
stimulation	NULL
elgg	NULL
.	NULL

mee	NULL
AME	NULL
IEI	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
TNF	NULL
.	NULL

Same	NULL
leg-	NULL
PMA	NULL
ends	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

B	NULL
,	NULL
same	NULL
as	NULL
A	NULL
except	NULL
that	NULL
ONO~	NULL
#	NULL
-	NULL
+	NULL
>	NULL
illlolo	NULL
st	NULL
malal	NULL
CD3*	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
.	NULL

C	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
IkBa	NULL
IVK	NULL
-	NULL
#	NULL
p	NULL
«	NULL
=	NULL
»	NULL
aam	NULL
»	NULL
«	NULL
am	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
«	NULL
B-luc-	NULL
(	NULL
0.4	NULL
ug	NULL
)	NULL
and	NULL
REPA/CAT	NULL
(	NULL
0.6	NULL
ug	NULL
)	NULL
reporter	NULL
plasmids	NULL
using	NULL
FuGENE6	NULL
method	NULL
.	NULL

Forty	NULL
hours	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
2	NULL
uM	NULL
GF	NULL
or	NULL
G6	NULL
for	NULL
15	NULL
min	NULL
and	NULL
then	NULL
stimulated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
(	NULL
-	NULL
)	NULL
with	NULL
PMA	NULL
and/or	NULL
ionomycin	NULL
for	NULL
4	NULL
h.	NULL
Equal	NULL
amounts	NULL
(	NULL
100	NULL
pl	NULL
)	NULL
of	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
and	NULL
CAT	NULL
expression	NULL
.	NULL

Luciferase	NULL
activity	NULL
is	NULL
normalized	NULL
to	NULL
CAT	NULL
expression	NULL
.	NULL

C	NULL
with	NULL
PD	NULL
.	NULL

Similarly	NULL
,	NULL
TNF-induced	NULL
IKK	NULL
activity	NULL
was	NULL
PD-insen-sitive	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
IKK	NULL
IP	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
PD	NULL
as	NULL
an	NULL
inhibitor	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
p90'®*	NULL
but	NULL
not	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
allowed	NULL
us	NULL
to	NULL
address	NULL
the	NULL
relative	NULL
role	NULL
of	NULL
each	NULL
IxBa	NULL
kinase	NULL
in	NULL
mediating	NULL
the	NULL
PMA	NULL
or	NULL
PMA-	NULL
and	NULL
ionomycin-dependent	NULL
IxBa	NULL
hyperphosphorylation	NULL
and	NULL
subsequent	NULL
degradation	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
same	NULL
cytosolic	NULL
extracts	NULL
from	NULL
purified	NULL
CD3¢*	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
used	NULL
for	NULL
the	NULL
p90'**	NULL
and	NULL
IKK	NULL
immunoprecipitations	NULL
experiments	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
analysis	NULL
and	NULL
immunoblotting	NULL
with	NULL
anti-IxBa-specific	NULL
antibodies	NULL
.	NULL

PMA	NULL
and	NULL
ionomycin	NULL
combined	NULL
,	NULL
but	NULL
not	NULL
PMA	NULL
,	NULL
or	NULL
ionomycin	NULL
alone	NULL
,	NULL
induced	NULL
a	NULL
slower	NULL
migration	NULL
form	NULL
of	NULL
IxBa	NULL
that	NULL
was	NULL
not	NULL
reversed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PD	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
in	NULL
vivo	NULL
IxBa	NULL
IB	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
in	NULL
vivo	NULL
relevance	NULL
of	NULL
the	NULL
regulation	NULL
of	NULL
I	NULL
«	NULL
xBa	NULL
phosphorylation	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
by	NULL
these	NULL
two	NULL
kinases	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
«	NULL
B-dependent	NULL
reporter	NULL
gene	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
PMA	NULL
alone	NULL
and	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
PD	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activity	NULL
by	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
was	NULL
minimally	NULL
sensitive	NULL
to	NULL
PD	NULL
.	NULL

Altogether	NULL
,	NULL
while	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
PMA	NULL
and	NULL
ionomycin	NULL
synergize	NULL
to	NULL
activate	NULL
in	NULL
vitro	NULL
the	NULL
IxBa	NULL
kinase	NULL
activity	NULL
of	NULL
both	NULL
the	NULL
IKK	NULL
complex	NULL
and	NULL
of	NULL
p90'®*	NULL
,	NULL
the	NULL
latter	NULL
is	NULL
not	NULL
regulated	NULL
by	NULL
calcineurin	NULL
and	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-KB	NULL
in	NULL
vivo	NULL
.	NULL

Conventional	NULL
PKC	NULL
Isoforms	NULL
Are	NULL
Required	NULL
for	NULL
the	NULL
Activation	NULL
of	NULL
the	NULL
IKK	NULL
Complex	NULL
in	NULL
T	NULL
Lymphocytes-Recent	NULL
studies	NULL
demonstrated	NULL
that	NULL
both	NULL
the	NULL
conventional	NULL
isoform	NULL
,	NULL
PKCa	NULL
,	NULL
and	NULL
the	NULL
in	NULL
vivo	NULL
|	NULL
IxBo	NULL
.	NULL

1B	NULL
***	NULL
«	NULL
==	NULL
«	NULL
s-	NULL
»	NULL
wees	NULL
cuse	NULL
cums	NULL
cuse	NULL
=	NULL
«	NULL
sum	NULL
cuses	NULL
muses	NULL
set	NULL
10	NULL
2	NULL
%	NULL
4	NULL
50	NULL
%	NULL
fo	NULL
8B	NULL
#	NULL
0	NULL
41	NULL
12	NULL
13	NULL
44	NULL
is	NULL
40000	NULL
-	NULL
Untreated	NULL
t	NULL
+GF	NULL
H	NULL
4	NULL
Gio	NULL
6976	NULL
>	NULL
30000	NULL
£	NULL
€	NULL
&	NULL
&	NULL
§	NULL
20000	NULL
3	NULL
®	NULL
&	NULL
g	NULL
10000	NULL
o	NULL
4	NULL
PMA	NULL
-	NULL
+	NULL
+	NULL
i	NULL
+	NULL
-	NULL
400+	NULL
IONQ	NULL
-	NULL
-	NULL
0	NULL
4	NULL
&	NULL
0	NULL
-	NULL
0	NULL
-	NULL
+	NULL
on	NULL
M	NULL
ie	NULL
I	NULL
t	NULL
:	NULL
novel	NULL
isoform	NULL
,	NULL
PKCO	NULL
,	NULL
may	NULL
be	NULL
potentially	NULL
involved	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

PKCa	NULL
associates	NULL
with	NULL
and	NULL
phosphorylates	NULL
IKK	NULL
(	NULL
41	NULL
)	NULL
suggesting	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
PKCa	NULL
following	NULL
TCR/CD3	NULL
cross-linking	NULL
could	NULL
result	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
.	NULL

PKC0	NULL
,	NULL
a	NULL
novel	NULL
PKC	NULL
isoform	NULL
was	NULL
recently	NULL
identified	NULL
as	NULL
the	NULL
PKC	NULL
isoform	NULL
that	NULL
synergizes	NULL
with	NULL
calcineurin	NULL
leading	NULL
to	NULL
JNK	NULL
activation	NULL
(	NULL
42	NULL
)	NULL
and	NULL
that	NULL
is	NULL
recruited	NULL
to	NULL
the	NULL
TCR	NULL
at	NULL
the	NULL
antigen-presenting	NULL
cells	NULL
docking	NULL
region	NULL
during	NULL
antigen	NULL
presentation	NULL
(	NULL
43	NULL
)	NULL
.	NULL

To	NULL
characterize	NULL
the	NULL
type	NULL
of	NULL
PKC	NULL
isoform	NULL
that	NULL
synergizes	NULL
with	NULL
calcineurin	NULL
to	NULL
activate	NULL
the	NULL
IKK	NULL
complex	NULL
,	NULL
a	NULL
series	NULL
of	NULL
pharmacological	NULL
inhibitors	NULL
of	NULL
PKC	NULL
were	NULL
utilized	NULL
(	NULL
44	NULL
)	NULL
.	NULL

GF109203X	NULL
(	NULL
GF	NULL
)	NULL
inhibits	NULL
the	NULL
conventional	NULL
and	NULL
novel	NULL
isoforms	NULL
,	NULL
whereas	NULL
G6	NULL
6976	NULL
(	NULL
G6	NULL
)	NULL
inhibits	NULL
only	NULL
the	NULL
conventional	NULL
isoforms	NULL
(	NULL
45	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
PKC	NULL
inhibitors	NULL
was	NULL
verified	NULL
by	NULL
using	NULL
TNF	NULL
as	NULL
a	NULL
PKC-independent	NULL
stimulus	NULL
that	NULL
leads	NULL
to	NULL
I	NULL
«	NULL
Ba	NULL
hyperphosphorylation	NULL
through	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
and	NULL
freshly	NULL
isolated	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
GF	NULL
followed	NULL
by	NULL
cell	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
analysis	NULL
of	NULL
the	NULL
IxBa	NULL
kinase	NULL
of	NULL
immunoprecipitated	NULL
IKK	NULL
.	NULL

GF	NULL
abrogated	NULL
the	NULL
IKK	NULL
complex	NULL
kinase	NULL
activation	NULL
triggered	NULL
by	NULL
PMA	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
with	NULL
ionomycin	NULL
in	NULL
both	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
2-4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
and	NULL
in	NULL
primary	NULL
CD3¢*	NULL
T	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

TNF	NULL
-induced	NULL
IKK	NULL
activation	NULL
was	NULL
not	NULL
reversed	NULL
by	NULL
GF	NULL
pretreatment	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
or	NULL
of	NULL
primary	NULL
CD3*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
from	NULL
previous	NULL
results	NULL
,	NULL
the	NULL
loss	NULL
of	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
in	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
but	NULL
not	NULL
in	NULL
TNF-treated	NULL
cells	NULL
preincubated	NULL
with	NULL
GF	NULL
directly	NULL
,	NULL
correlates	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
I	NULL
«	NULL
xBa	NULL
hyperphosphorylation	NULL
in	NULL
vivo	NULL
observed	NULL
in	NULL
I	NULL
«	NULL
Ba	NULL
immunoblots	NULL
of	NULL
the	NULL
same	NULL
cytosolic	NULL
samples	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
in	NULL
vivo	NULL
IxBa	NULL
IB	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
confirm	NULL
the	NULL
requirement	NULL
for	NULL
a	NULL
conventional	NULL
or	NULL
novel	NULL
isoform	NULL
of	NULL
PKC	NULL
for	NULL
the	NULL
synergistic	NULL
IKK	NULL
activity	NULL
.	NULL

Because	NULL
GF	NULL
can	NULL
inhibit	NULL
both	NULL
conventional	NULL
(	NULL
«	NULL
,	NULL
B	NULL
,	NULL
y	NULL
)	NULL
and	NULL
novel	NULL
(	NULL
e	NULL
,	NULL
0	NULL
,	NULL
8	NULL
,	NULL
n	NULL
,	NULL
1	NULL
)	NULL
PKC	NULL
isoforms	NULL
(	NULL
44	NULL
)	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
identify	NULL
which	NULL
subgroup	NULL
of	NULL
the	NULL
PMA-responsive	NULL
PKC	NULL
isoforms	NULL
was	NULL
mediating	NULL
the	NULL
synergy	NULL
with	NULL
calcineurin	NULL
.	NULL

We	NULL
predicted	NULL
that	NULL
if	NULL
PKCQ	NULL
would	NULL
be	NULL
the	NULL
PKC	NULL
isoform	NULL
that	NULL
synergized	NULL
with	NULL
calcineurin	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
pretreatment	NULL
with	NULL
GS	NULL
would	NULL
not	NULL
inhibit	NULL
the	NULL
PMA	NULL
and	NULL
ionomycin-induced	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
and	NULL
,	NULL
hence	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
I	NULL
«	NULL
Ba	NULL
hyperphosphorylation	NULL
.	NULL

To	NULL
test	NULL
this	NULL
,	NULL
Jurkat	NULL
T	NULL
lymphocytes	NULL
and	NULL
freshly	NULL
isolated	NULL
primary	NULL
CD3¢	NULL
T	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
G6	NULL
,	NULL
followed	NULL
by	NULL
their	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
and	NULL
analysis	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
activity	NULL
.	NULL

G6	NULL
selectively	NULL
inhibited	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
mediated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
in	NULL
both	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
and	NULL
10	NULL
,	NULL
11	NULL
)	NULL
and	NULL
in	NULL
primary	NULL
CD3¢*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
IxBa	NULL
IVK	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
and	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

G6	NULL
pretreatment	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
TNF-induced	NULL
IKK	NULL
complex	NULL
kinase	NULL
activation	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
12	NULL
)	NULL
or	NULL
in	NULL
primary	NULL
CD3¢*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
IxBa	NULL
IVK	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
15	NULL
)	NULL
.	NULL

The	NULL
Gé-dependent	NULL
inhibition	NULL
of	NULL
IKK	NULL
complex	NULL
activity	NULL
triggered	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
directly	NULL
correlated	NULL
with	NULL
the	NULL
abrogation	NULL
of	NULL
the	NULL
PMA-	NULL
and	NULL
ionomycin-induced	NULL
IxBa	NULL
hyperphosphorylation	NULL
in	NULL
vivo	NULL
in	NULL
both	NULL
types	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
in	NULL
vivo	NULL
IxBa	NULL
IB	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
TNF-mediated	NULL
IxBa	NULL
hyperphosphorylation	NULL
in	NULL
vivo	NULL
was	NULL
not	NULL
reversed	NULL
by	NULL
GO	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
in	NULL
vivo	NULL
IxBa	NULL
IB	NULL
)	NULL
.	NULL

The	NULL
functional	NULL
relevance	NULL
of	NULL
these	NULL
observations	NULL
was	NULL
evaluated	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
xB	NULL
reporter	NULL
gene	NULL
and	NULL
stimulated	NULL
or	NULL
not	NULL
with	NULL
PMA	NULL
or	NULL
PMA	NULL
and	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
not	NULL
of	NULL
GF	NULL
and	NULL
G6	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
both	NULL
GF	NULL
and	NULL
Go	NULL
specifically	NULL
inhibited	NULL
the	NULL
PMA	NULL
and	NULL
PMA-	NULL
and	NULL
ionomycin-induced	NULL
but	NULL
not	NULL
the	NULL
basal	NULL
NF-	NULL
«	NULL
B-dependent	NULL
transcriptional	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
conventional	NULL
PKC	NULL
isoforms	NULL
mediate	NULL
the	NULL
PMA	NULL
effects	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
IKK	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
contribution	NULL
of	NULL
this	NULL
subfamily	NULL
of	NULL
PKC	NULL
isoforms	NULL
to	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
calcineurin	NULL
,	NULL
wild-type	NULL
of	NULL
PKCa	NULL
was	NULL
overexpressed	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
constitutively	NULL
active	NULL
form	NULL
of	NULL
calcineurin	NULL
ACam-AlI	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Overexpression	NULL
of	NULL
PKCa-wt	NULL
or	NULL
ACam-AI	NULL
alone	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

However	NULL
,	NULL
stimulation	NULL
of	NULL
PKCa-wt-transfected	NULL
Jurkat	NULL
T	NULL
cell	NULL
with	NULL
PMA	NULL
resulted	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
to	NULL
a	NULL
degree	NULL
similar	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
co-stimulation	NULL
in	NULL
mock-transfected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
co-expression	NULL
of	NULL
PKCa-wt	NULL
and	NULL
ACam-Al	NULL
resulted	NULL
in	NULL
a	NULL
synergistic	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
different	NULL
from	NULL
the	NULL
activation	NULL
of	NULL
another	NULL
cellular	NULL
kinase	NULL
,	NULL
JNK	NULL
,	NULL
conventional	NULL
PKC	NULL
isoforms	NULL
such	NULL
as	NULL
PKCa	NULL
can	NULL
mediate	NULL
the	NULL
synergistic	NULL
interaction	NULL
with	NULL
calcineurin	NULL
following	NULL
TCR/CD3	NULL
cross-linking	NULL
that	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
kinase	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
Dominant	NULL
Negative	NULL
Form	NULL
of	NULL
IKKB	NULL
Blocks	NULL
NF-	NULL
«	NULL
B	NULL
Activation	NULL
Triggered	NULL
by	NULL
PKC-	NULL
and	NULL
Calcineurin-dependent	NULL
Pathways-By	NULL
having	NULL
demonstrated	NULL
that	NULL
calcineurin	NULL
synergizes	NULL
with	NULL
PKC	NULL
to	NULL
activate	NULL
the	NULL
IKK	NULL
complex	NULL
,	NULL
we	NULL
next	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
dominant	NULL
negative	NULL
forms	NULL
of	NULL
IKKa	NULL
and	NULL
IKKB	NULL
on	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
that	NULL
follows	NULL
PMA-ionomycin	NULL
cell	NULL
stimulation	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
co-transfected	NULL
with	NULL
expression	NULL
vectors	NULL
of	NULL
dominant	NULL
negative	NULL
IKK	NULL
genes	NULL
and	NULL
luciferase	NULL
reporter	NULL
genes	NULL
driven	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
concatamers	NULL
.	NULL

Rous	NULL
sarcoma	NULL
virus-CAT	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
of	NULL
transfection	NULL
efficiency	NULL
and	NULL
cell	NULL
toxicity	NULL
.	NULL

22929	NULL
itn	NULL
J	NULL
untReateDp	NULL
Moco	NULL
,	NULL
:	NULL
:	NULL
:	NULL
+ION0	NULL
7	NULL
§	NULL
777	NULL
Z	NULL
A	NULL
A	NULL
w	NULL
__	NULL
_	NULL
#	NULL
A	NULL
#	NULL
522°	NULL
``	NULL
?	NULL

?	NULL

?	NULL

peDNA3	NULL
PKCa-wt	NULL
_	NULL
ACaM-Al	NULL
_	NULL
ACaM-Al	NULL
I	NULL
+	NULL
PKCa-wt	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

PKCa	NULL
synergizes	NULL
with	NULL
calcineurin	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
«	NULL
B-lue-	NULL
(	NULL
0.4	NULL
ug	NULL
)	NULL
and	NULL
REPA/CAT	NULL
(	NULL
0.6	NULL
pug	NULL
)	NULL
reporter	NULL
plasmids	NULL
,	NULL
pME18S-PKCa-wild-type	NULL
(	NULL
PKCa-wt	NULL
)	NULL
(	NULL
0.5	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
pSRa4ACaM-AI	NULL
(	NULL
ACaM-AI	NULL
)	NULL
encoding	NULL
a	NULL
constitutively	NULL
active	NULL
calcineurin	NULL
catalytic	NULL
subunit	NULL
(	NULL
0.5	NULL
pg	NULL
)	NULL
.	NULL

Forty	NULL
hours	NULL
later	NULL
cells	NULL
were	NULL
stimulated	NULL
or	NULL
not	NULL
with	NULL
PMA	NULL
and/or	NULL
ionomycin	NULL
(	NULL
FONO	NULL
)	NULL
for	NULL
4	NULL
h	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Equal	NULL
amounts	NULL
(	NULL
100	NULL
ul	NULL
)	NULL
of	NULL
cytosolic	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
luciferase	NULL
and	NULL
CAT	NULL
expression	NULL
.	NULL

Luciferase	NULL
activity	NULL
is	NULL
normalized	NULL
to	NULL
CAT	NULL
expression	NULL
(	NULL
relative	NULL
luciferase	NULL
activity	NULL
)	NULL
.	NULL

All	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

12000	NULL
[	NULL
]	NULL
Unstimulated	NULL
J	NULL
PMA	NULL
EB	NULL
PMA/ONO	NULL
100004	NULL
8000	NULL
4	NULL
6000	NULL
{	NULL
4000	NULL
4	NULL
Relative	NULL
luciferase	NULL
activity	NULL
2000	NULL
7	NULL
IKKo-KD	NULL
o	NULL
peDNA	NULL
3	NULL
IKKB-KD	NULL
IKKo-KD	NULL
IKKB-KD	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Dominant	NULL
negative	NULL
form	NULL
of	NULL
IKK	NULL
$	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
triggered	NULL
by	NULL
conventional	NULL
PKCs	NULL
and	NULL
calcineurin	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
B-luc	NULL
reporter	NULL
plasmid	NULL
and	NULL
the	NULL
following	NULL
plasmids	NULL
:	NULL
peDNAS-IKKa-kinase	NULL
dead	NULL
(	NULL
IKKa	NULL
KD	NULL
)	NULL
and	NULL
pRKS5-C-Flag-IKK	NULL
$	NULL
G-kinase	NULL
dead	NULL
(	NULL
IKKS	NULL
KD	NULL
)	NULL
using	NULL
FuGENE6	NULL
method	NULL
.	NULL

The	NULL
total	NULL
DNA	NULL
amount	NULL
was	NULL
normalized	NULL
up	NULL
to	NULL
2	NULL
ug	NULL
with	NULL
peDNAS	NULL
.	NULL

Forty	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
prior	NULL
to	NULL
harvest	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
JONO	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
normalized	NULL
to	NULL
CAT	NULL
expression	NULL
of	NULL
the	NULL
pREP4/CAT	NULL
plasmid	NULL
.	NULL

Overexpression	NULL
of	NULL
IKKS	NULL
kinase	NULL
dead	NULL
(	NULL
KD	NULL
)	NULL
,	NULL
but	NULL
not	NULL
the	NULL
wild-type	NULL
isoforms	NULL
of	NULL
IKKa	NULL
or	NULL
-B	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
selectively	NULL
impaired	NULL
both	NULL
PMA	NULL
and	NULL
PMA/ionomycin-induced	NULL
up-regulation	NULL
of	NULL
NF-	NULL
«	NULL
B-driven	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
overexpression	NULL
of	NULL
the	NULL
IKKa-DN	NULL
alone	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
and	NULL
its	NULL
combination	NULL
with	NULL
the	NULL
IKKfB-DN	NULL
did	NULL
not	NULL
enhance	NULL
the	NULL
inhibition	NULL
achieved	NULL
by	NULL
IKKB-DN	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
extend	NULL
and	NULL
confirm	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
in	NULL
the	NULL
convergence	NULL
of	NULL
the	NULL
PKC	NULL
and	NULL
calcineurin	NULL
signal	NULL
transduction	NULL
pathways	NULL
to	NULL
mediate	NULL
IxBa	NULL
hyperphosphorylation-degradation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

DISCUSSION	NULL
The	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
study	NULL
identify	NULL
the	NULL
molecular	NULL
targets	NULL
and	NULL
mechanisms	NULL
whereby	NULL
two	NULL
TCR/CD3-dependent	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
22930	NULL
second	NULL
messengers	NULL
,	NULL
PKC	NULL
and	NULL
calcineurin	NULL
,	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

The	NULL
identification	NULL
that	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
are	NULL
effective	NULL
inhibitors	NULL
of	NULL
IKK	NULL
activation	NULL
advances	NULL
our	NULL
knowledge	NULL
as	NULL
to	NULL
the	NULL
function	NULL
of	NULL
these	NULL
commonly	NULL
used	NULL
immunosuppressive	NULL
agents	NULL
.	NULL

Moreover	NULL
,	NULL
our	NULL
results	NULL
highlight	NULL
the	NULL
essential	NULL
role	NULL
that	NULL
conventional	NULL
PKC	NULL
isoforms	NULL
play	NULL
in	NULL
the	NULL
TCR-mediated	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
molecules	NULL
that	NULL
should	NULL
be	NULL
considered	NULL
as	NULL
targets	NULL
for	NULL
future	NULL
drug	NULL
development	NULL
with	NULL
the	NULL
aim	NULL
of	NULL
interfering	NULL
with	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
involved	NULL
in	NULL
multiple	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
(	NULL
47	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
cross-linking	NULL
results	NULL
in	NULL
NF-kB	NULL
activation	NULL
(	NULL
48-51	NULL
)	NULL
and	NULL
together	NULL
with	NULL
NF-AT	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
octomer	NULL
leads	NULL
to	NULL
IL-2	NULL
expression	NULL
in	NULL
in	NULL
vitro	NULL
experimental	NULL
settings	NULL
(	NULL
52-54	NULL
)	NULL
.	NULL

However	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
play	NULL
a	NULL
more	NULL
significant	NULL
role	NULL
in	NULL
regulating	NULL
T	NULL
cell	NULL
function	NULL
in	NULL
vivo	NULL
than	NULL
that	NULL
inferred	NULL
from	NULL
studies	NULL
analyzing	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
IL-2	NULL
production	NULL
is	NULL
greatly	NULL
impaired	NULL
in	NULL
c-Rel-deficient	NULL
lymphocytes	NULL
(	NULL
55	NULL
)	NULL
and	NULL
in	NULL
T	NULL
cells	NULL
with	NULL
constitutive	NULL
repression	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
(	NULL
56	NULL
)	NULL
suggests	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
rather	NULL
than	NULL
only	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
is	NULL
required	NULL
for	NULL
an	NULL
adequate	NULL
T	NULL
cell	NULL
function	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
identification	NULL
of	NULL
calcineurin	NULL
as	NULL
a	NULL
necessary	NULL
component	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IKK	NULL
by	NULL
TCR	NULL
engagement	NULL
and	NULL
the	NULL
complete	NULL
inhibition	NULL
of	NULL
NF-B	NULL
activation	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
may	NULL
explain	NULL
the	NULL
effectiveness	NULL
of	NULL
such	NULL
drugs	NULL
as	NULL
NF-	NULL
«	NULL
B-specific	NULL
T	NULL
cell	NULL
activation	NULL
inhibitors	NULL
.	NULL

The	NULL
relevance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
as	NULL
a	NULL
target	NULL
of	NULL
TCR	NULL
engagement	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
understanding	NULL
the	NULL
immune	NULL
response	NULL
but	NULL
to	NULL
other	NULL
relevant	NULL
areas	NULL
such	NULL
as	NULL
HIV	NULL
pathogenesis	NULL
.	NULL

Recent	NULL
studies	NULL
indicate	NULL
that	NULL
T	NULL
lymphocytes	NULL
serve	NULL
as	NULL
a	NULL
reservoir	NULL
of	NULL
latent	NULL
HIV	NULL
provirus	NULL
in	NULL
patients	NULL
effectively	NULL
responding	NULL
to	NULL
highly	NULL
active	NULL
antiretroviral	NULL
therapy	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
key	NULL
transcription	NULL
factor	NULL
in	NULL
reactivating	NULL
HIV	NULL
from	NULL
latency	NULL
in	NULL
T	NULL
lymphocytes	NULL
explains	NULL
the	NULL
HIV	NULL
reactivation	NULL
and	NULL
viral	NULL
production	NULL
that	NULL
ensues	NULL
following	NULL
T	NULL
cell	NULL
receptor	NULL
activation	NULL
of	NULL
latent	NULL
HIV-in-fected	NULL
T	NULL
cells	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
calcineurin	NULL
or	NULL
of	NULL
conventional	NULL
PKC	NULL
isoform	NULL
as	NULL
potential	NULL
targets	NULL
of	NULL
this	NULL
process	NULL
could	NULL
be	NULL
of	NULL
future	NULL
value	NULL
in	NULL
the	NULL
study	NULL
of	NULL
HIV	NULL
reactivation	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
find	NULL
that	NULL
the	NULL
IKK	NULL
complex	NULL
,	NULL
and	NULL
not	NULL
p90'**	NULL
,	NULL
mediates	NULL
IxBa	NULL
hyperphosphorylation	NULL
at	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
and	NULL
thus	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
vivo	NULL
following	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
.	NULL

This	NULL
observation	NULL
highlights	NULL
that	NULL
while	NULL
both	NULL
kinases	NULL
are	NULL
activated	NULL
by	NULL
PKC-dependent	NULL
pathways	NULL
and	NULL
further	NULL
amplified	NULL
in	NULL
a	NULL
synergistic	NULL
manner	NULL
by	NULL
Ca*	NULL
``	NULL
*-dependent	NULL
pathways	NULL
,	NULL
only	NULL
the	NULL
IKK	NULL
complex	NULL
appears	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
via	NULL
IxBa	NULL
.	NULL

Although	NULL
IxBa	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
may	NULL
prove	NULL
to	NULL
be	NULL
a	NULL
good	NULL
in	NULL
vitro	NULL
substrate	NULL
to	NULL
measure	NULL
p90'®*	NULL
activity	NULL
,	NULL
its	NULL
in	NULL
vivo	NULL
extrapolation	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
may	NULL
be	NULL
less	NULL
certain	NULL
.	NULL

We	NULL
conclude	NULL
this	NULL
from	NULL
the	NULL
fact	NULL
that	NULL
p90'**	NULL
and	NULL
IKK	NULL
do	NULL
not	NULL
co-immunoprecipitate	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
,	NULL
more	NULL
im-portantly	NULL
,	NULL
that	NULL
a	NULL
MEK	NULL
inhibitor	NULL
(	NULL
PD	NULL
)	NULL
does	NULL
not	NULL
affect	NULL
IKK	NULL
activation	NULL
or	NULL
IxBa	NULL
phosphorylation	NULL
in	NULL
vivo	NULL
followed	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
,	NULL
whereas	NULL
it	NULL
completely	NULL
inhibits	NULL
p90'®*	NULL
activation	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
the	NULL
MEK	NULL
inhibitor	NULL
spares	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
leading	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
from	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathway	NULL
may	NULL
be	NULL
of	NULL
future	NULL
value	NULL
in	NULL
selectively	NULL
inhibiting	NULL
and	NULL
differentiating	NULL
specific	NULL
target	NULL
functions	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
such	NULL
as	NULL
NF-	NULL
«	NULL
B	NULL
versus	NULL
API	NULL
mitogen-activated	NULL
protein	NULL
kinase-dependent	NULL
activation	NULL
.	NULL

IKKa	NULL
and	NULL
-B	NULL
are	NULL
contained	NULL
within	NULL
a	NULL
high	NULL
molecular	NULL
weight	NULL
complex	NULL
with	NULL
multiple	NULL
components	NULL
(	NULL
24	NULL
,	NULL
27	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
dominant	NULL
negative	NULL
forms	NULL
of	NULL
IKK	NULL
on	NULL
NF-KB	NULL
activation	NULL
suggests	NULL
that	NULL
this	NULL
kinase	NULL
is	NULL
relevant	NULL
in	NULL
mediating	NULL
the	NULL
synergistic	NULL
activation	NULL
of	NULL
NF-kB	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PKC	NULL
and	NULL
calcineurin	NULL
.	NULL

The	NULL
role	NULL
of	NULL
IKKa	NULL
in	NULL
this	NULL
process	NULL
is	NULL
less	NULL
clear	NULL
.	NULL

Although	NULL
overexpression	NULL
of	NULL
dominant	NULL
negative	NULL
forms	NULL
of	NULL
IKKa	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
PMA	NULL
and	NULL
ionomycin-induced	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
,	NULL
both	NULL
endogenous	NULL
IKKa	NULL
and	NULL
IKK	NULL
become	NULL
in	NULL
vivo	NULL
hy-perphosphorylated	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
thus	NULL
suggesting	NULL
that	NULL
activation	NULL
of	NULL
both	NULL
kinases	NULL
may	NULL
be	NULL
needed	NULL
for	NULL
full	NULL
signalsome	NULL
activity	NULL
.	NULL

Prior	NULL
studies	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
demonstrated	NULL
that	NULL
IKK	NULL
rather	NULL
then	NULL
IKKa	NULL
played	NULL
a	NULL
major	NULL
role	NULL
in	NULL
IxBa	NULL
phosphorylation	NULL
by	NULL
TNF	NULL
,	NULL
potentially	NULL
explaining	NULL
the	NULL
stronger	NULL
effect	NULL
of	NULL
overexpressed	NULL
IKK	NULL
on	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
observed	NULL
in	NULL
these	NULL
studies	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
whereby	NULL
calcineurin	NULL
converges	NULL
with	NULL
PKC-dependent	NULL
pathways	NULL
to	NULL
activate	NULL
the	NULL
IKK	NULL
complex	NULL
is	NULL
unknown	NULL
.	NULL

Previous	NULL
studies	NULL
from	NULL
our	NULL
group	NULL
indicated	NULL
that	NULL
calcineurin	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
T	NULL
lymphocytes	NULL
(	NULL
11	NULL
)	NULL
.	NULL

However	NULL
,	NULL
its	NULL
presence	NULL
was	NULL
required	NULL
in	NULL
order	NULL
for	NULL
PKC-dependent	NULL
pathways	NULL
to	NULL
induce	NULL
a	NULL
maximal	NULL
level	NULL
of	NULL
NF-KB	NULL
activation	NULL
(	NULL
11	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Results	NULL
presented	NULL
here	NULL
extend	NULL
and	NULL
confirm	NULL
those	NULL
observations	NULL
by	NULL
documenting	NULL
that	NULL
the	NULL
level	NULL
of	NULL
IKK	NULL
activation	NULL
triggered	NULL
by	NULL
PKC-dependent	NULL
pathways	NULL
is	NULL
only	NULL
moderate	NULL
and	NULL
that	NULL
increased	NULL
(	NULL
Ca®*	NULL
)	NULL
levels	NULL
alone	NULL
are	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
IKK	NULL
.	NULL

Rather	NULL
,	NULL
increased	NULL
(	NULL
Ca**	NULL
)	NULL
levels	NULL
need	NULL
to	NULL
be	NULL
present	NULL
at	NULL
the	NULL
time	NULL
of	NULL
PKC	NULL
activation	NULL
to	NULL
result	NULL
in	NULL
maximum	NULL
IKK	NULL
activity	NULL
and	NULL
hence	NULL
in	NULL
vivo	NULL
IxBa	NULL
phosphorylation	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
calcineurin	NULL
alone	NULL
does	NULL
not	NULL
activate	NULL
IKK	NULL
does	NULL
not	NULL
exclude	NULL
that	NULL
it	NULL
does	NULL
not	NULL
target	NULL
the	NULL
IKK	NULL
complex	NULL
.	NULL

Potentially	NULL
,	NULL
calcineurin	NULL
may	NULL
modify	NULL
the	NULL
composition	NULL
or	NULL
interaction	NULL
of	NULL
proteins	NULL
with	NULL
the	NULL
signalsome	NULL
.	NULL

This	NULL
could	NULL
allow	NULL
for	NULL
a	NULL
more	NULL
effective	NULL
activation	NULL
of	NULL
the	NULL
signalsome	NULL
by	NULL
PKC-dependent	NULL
pathways	NULL
.	NULL

Alternatively	NULL
,	NULL
calcineurin	NULL
may	NULL
function	NULL
upstream	NULL
of	NULL
the	NULL
signalsome	NULL
by	NULL
modifying	NULL
transducers	NULL
of	NULL
the	NULL
PKC-dependent	NULL
pathway	NULL
resulting	NULL
in	NULL
a	NULL
more	NULL
effective	NULL
downstream	NULL
activation	NULL
of	NULL
IKK	NULL
by	NULL
PKC	NULL
.	NULL

Future	NULL
studies	NULL
need	NULL
to	NULL
address	NULL
these	NULL
and	NULL
other	NULL
possibilities	NULL
,	NULL
which	NULL
should	NULL
ultimately	NULL
lead	NULL
to	NULL
the	NULL
identification	NULL
of	NULL
potential	NULL
targets	NULL
of	NULL
new	NULL
immunosuppressive	NULL
agents	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
conventional	NULL
PKC	NULL
isoforms	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IKK	NULL
complex	NULL
activation	NULL
is	NULL
of	NULL
potential	NULL
relevance	NULL
.	NULL

By	NULL
using	NULL
specific	NULL
pharmacological	NULL
inhibitors	NULL
in	NULL
primary	NULL
CD3	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
T	NULL
cell-specific	NULL
classical	NULL
PKC	NULL
isoforms	NULL
such	NULL
as	NULL
«	NULL
or	NULL
BI	NULL
must	NULL
be	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
(	NULL
58-62	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
which	NULL
of	NULL
these	NULL
PKC	NULL
isoforms	NULL
that	NULL
mediate	NULL
the	NULL
activation	NULL
of	NULL
IKK	NULL
needs	NULL
to	NULL
be	NULL
pursued	NULL
.	NULL

The	NULL
recent	NULL
observation	NULL
that	NULL
PKCa	NULL
can	NULL
directly	NULL
interact	NULL
and	NULL
activate	NULL
IKKB	NULL
but	NULL
not	NULL
IKKa	NULL
(	NULL
41	NULL
)	NULL
suggests	NULL
that	NULL
PKCa	NULL
can	NULL
directly	NULL
mediate	NULL
TCRCD3-generated	NULL
signals	NULL
to	NULL
the	NULL
IKK	NULL
complex	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
whereas	NULL
PKCO	NULL
is	NULL
activated	NULL
during	NULL
antigen	NULL
presentation	NULL
(	NULL
43	NULL
)	NULL
and	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
AP-1	NULL
transcriptional	NULL
activity	NULL
(	NULL
42	NULL
,	NULL
63	NULL
)	NULL
,	NULL
its	NULL
lack	NULL
of	NULL
cytoplasmic	NULL
membrane	NULL
translocation	NULL
following	NULL
TCR/CD3	NULL
activation	NULL
,	NULL
together	NULL
with	NULL
results	NULL
presented	NULL
here	NULL
,	NULL
suggests	NULL
that	NULL
this	NULL
T	NULL
lymphocyte-specific	NULL
PKC	NULL
isoform	NULL
may	NULL
participate	NULL
in	NULL
signal	NULL
transduction	NULL
pathways	NULL
activated	NULL
following	NULL
antigen	NULL
presentation	NULL
,	NULL
separate	NULL
from	NULL
those	NULL
initiated	NULL
from	NULL
TCR/	NULL
CD3	NULL
.	NULL

Antigen	NULL
presentation	NULL
requires	NULL
not	NULL
only	NULL
the	NULL
activation	NULL
of	NULL
TCR/CD3	NULL
,	NULL
but	NULL
also	NULL
of	NULL
other	NULL
co-stimulatory	NULL
receptors	NULL
such	NULL
as	NULL
CD28	NULL
.	NULL

The	NULL
recent	NULL
report	NULL
(	NULL
64	NULL
)	NULL
demonstrating	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
CD3-	NULL
and	NULL
CD28-generated	NULL
signals	NULL
converge	NULL
on	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
3-type	NULL
kinase	NULL
,	NULL
Cot	NULL
,	NULL
suggests	NULL
that	NULL
the	NULL
process	NULL
of	NULL
antigen	NULL
presentation	NULL
that	NULL
leads	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
may	NULL
require	NULL
the	NULL
separate	NULL
but	NULL
coordinated	NULL
activation	NULL
of	NULL
at	NULL
least	NULL
TCR/CD3	NULL
and	NULL
CD28	NULL
signaling	NULL
pathways	NULL
,	NULL
each	NULL
one	NULL
with	NULL
distinct	NULL
but	NULL
necessary	NULL
second	NULL
messages	NULL
.	NULL

Future	NULL
studies	NULL
should	NULL
address	NULL
how	NULL
two	NULL
necessary	NULL
components	NULL
of	NULL
the	NULL
TCR/CD3-initiated	NULL
pathways	NULL
,	NULL
conventional	NULL
PKC	NULL
isoforms	NULL
and	NULL
calcineurin	NULL
,	NULL
interact	NULL
with	NULL
the	NULL
CD28-dependent	NULL
second	NULL
messengers	NULL
to	NULL
effectively	NULL
activate	NULL
NF-kB	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Gary	NULL
Bren	NULL
for	NULL
outstanding	NULL
technical	NULL
assistance	NULL
and	NULL
all	NULL
the	NULL
members	NULL
of	NULL
Dr.	NULL
Paya	NULL
's	NULL
laboratory	NULL
for	NULL
thoughtful	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
PKC	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IKK	NULL
discussions	NULL
.	NULL

We	NULL
thank	NULL
Teresa	NULL
Hoff	NULL
for	NULL
excellent	NULL
manuscript	NULL
preparation	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
2	NULL
.	NULL

Guerder	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Flavell	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Intern	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

18	NULL
,	NULL
135-146	NULL
3	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
826	NULL
,	NULL
711-713	NULL
4	NULL
.	NULL

Gaynor	NULL
,	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
AIDS	NULL
6	NULL
,	NULL
347-363	NULL
5	NULL
.	NULL

Imboded	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161	NULL
,	NULL
446-456	NULL
6	NULL
.	NULL

Berridge	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Nature	NULL
861	NULL
,	NULL
815-825	NULL
7	NULL
.	NULL

Clapham	NULL
,	NULL
D.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
259-268	NULL
8	NULL
.	NULL

Truneh	NULL
,	NULL
A.	NULL
,	NULL
Albert	NULL
,	NULL
F.	NULL
,	NULL
Golstein	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Schmitt-Verhulst	NULL
,	NULL
A.-M.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
t	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

18	NULL
.	NULL

14	NULL
.	NULL

15.	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Scheinman	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Haskill	NULL
,	NULL
S.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

813	NULL
,	NULL
318-320	NULL
.	NULL

O'Keefe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
692-694	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Clipstone	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63	NULL
,	NULL
1045-1083	NULL
Frantz	NULL
,	NULL
B.	NULL
,	NULL
Nordby	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Bren	NULL
,	NULL
G.	NULL
,	NULL
Steffan	NULL
,	NULL
N.	NULL
,	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
O'Keefe	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

18	NULL
,	NULL
861-870	NULL
Sen	NULL
,	NULL
J.	NULL
,	NULL
Venkataraman	NULL
,	NULL
L.	NULL
,	NULL
Shinkai	NULL
,	NULL
Y.	NULL
,	NULL
Pierce	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Alt	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Burakoff	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
and	NULL
Sen	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

154	NULL
,	NULL
8218-8221	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Blank	NULL
,	NULL
V.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Vandekerckhove	NULL
,	NULL
J.	NULL
,	NULL
Lottspeich	NULL
,	NULL
F.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Urban	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
62	NULL
,	NULL
1007-1018	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Liou	NULL
,	NULL
H.-C.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
961-969	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

3	NULL
,	NULL
1689-1698	NULL
Baldwin	NULL
A.	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

6	NULL
,	NULL
1899-1913	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
DiDonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Rosette	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Karin	NULL
M.	NULL
(	NULL
19938	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
705-718	NULL
Thompson	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Phillips	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Bromage	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Ghosh	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
573-582	NULL
Brown	NULL
,	NULL
K.	NULL
,	NULL
Gerstberger	NULL
,	NULL
S.	NULL
,	NULL
Carlson	NULL
,	NULL
L.	NULL
,	NULL
Franzoso	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Science	NULL
267	NULL
,	NULL
1485-1488	NULL
Brockman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Scherer	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
McKinsey	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Hall	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Qi	NULL
,	NULL
X.	NULL
,	NULL
Lee	NULL
,	NULL
W.	NULL
Y.	NULL
,	NULL
and	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
2809-2818	NULL
DiDonato	NULL
,	NULL
J.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
Rosette	NULL
,	NULL
C.	NULL
,	NULL
Wu-Li	NULL
,	NULL
J.	NULL
,	NULL
Suyang	NULL
,	NULL
H.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
1295-1304	NULL
Traenckner	NULL
,	NULL
E.	NULL
B.-M.	NULL
,	NULL
Pabl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Henkel	NULL
,	NULL
T.	NULL
,	NULL
Schmidt	NULL
,	NULL
K.	NULL
N.	NULL
,	NULL
Wilk	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

14	NULL
,	NULL
2876-2883	NULL
Whiteside	NULL
,	NULL
S	NULL
,	NULL
T.	NULL
,	NULL
Ernst	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
LeBail	NULL
,	NULL
O.	NULL
,	NULL
Laurent-Winter	NULL
,	NULL
C.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
5389-5345	NULL
DiDonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hayakawa	NULL
,	NULL
M.	NULL
,	NULL
Rothwarf	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Zandi	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
888	NULL
,	NULL
548-554	NULL
Zandi	NULL
,	NULL
E.	NULL
,	NULL
Rothwarf	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Delhase	NULL
,	NULL
M.	NULL
,	NULL
Hayakawa	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Cell	NULL
91	NULL
,	NULL
248-252	NULL
Regnier	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Song	NULL
,	NULL
H.	NULL
Y.	NULL
,	NULL
Gao	NULL
,	NULL
X.	NULL
,	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
,	NULL
Cao	NULL
,	NULL
Z.	NULL
,	NULL
and	NULL
Rothe	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Cell	NULL
90	NULL
,	NULL
373-383	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
Zhu	NULL
,	NULL
H.	NULL
,	NULL
Murray	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Shevchenko	NULL
,	NULL
A.	NULL
,	NULL
Bennett	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
D.	NULL
B.Li	NULL
,	NULL
J.	NULL
Wu	NULL
,	NULL
Young	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Barbosa	NULL
,	NULL
M.	NULL
,	NULL
Mann	NULL
,	NULL
M.	NULL
,	NULL
Manning	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
860-866	NULL
Woronicz	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Gao	NULL
,	NULL
X.	NULL
,	NULL
Cao	NULL
,	NULL
Z.	NULL
,	NULL
Rothe	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Goeddel	NULL
,	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
866-869	NULL
Ghoda	NULL
,	NULL
L.	NULL
,	NULL
Lin	NULL
,	NULL
X.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
21281-21288	NULL
Schouten	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Vertegaal	NULL
,	NULL
A.	NULL
C.	NULL
O.	NULL
,	NULL
Whiteside	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
Israél	NULL
,	NULL
A.	NULL
,	NULL
Toebes	NULL
,	NULL
M.	NULL
,	NULL
Dorsman	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Zanterna	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

16	NULL
,	NULL
3133-3143	NULL
Steffan	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
Bren	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
Frantz	NULL
,	NULL
B.	NULL
,	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
O'Neill	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

155	NULL
,	NULL
4685-4691	NULL
McElhinny	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
MacMorran	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Bren	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
Ten	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Israél	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
1500-1509	NULL
Kincaid	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Giri	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Higuchi	NULL
,	NULL
S.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Dixon	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Marietta	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37.	NULL
.	NULL

Liu	NULL
,	NULL
J.	NULL
,	NULL
Farmer	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Friedman	NULL
,	NULL
J.	NULL
,	NULL
Weissman	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Schreiber	NULL
,	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

22931	NULL
Amorese	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
Martin	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
11812-11319	NULL
Algeciras-Schimnich	NULL
,	NULL
A.	NULL
,	NULL
Griffith	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
Lynch	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
and	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1999	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

162	NULL
,	NULL
5205-5211	NULL
Haskill	NULL
,	NULL
S.	NULL
,	NULL
Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Tompkins	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Morris	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Yurochko	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sampson-Johannes	NULL
,	NULL
A.	NULL
,	NULL
Mondal	NULL
,	NULL
K.	NULL
,	NULL
Ralph	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Jr.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
1281-1289	NULL
Brown	NULL
,	NULL
K.	NULL
,	NULL
Franzoso	NULL
,	NULL
G.	NULL
,	NULL
Baldi	NULL
,	NULL
L.	NULL
,	NULL
Carlson	NULL
,	NULL
L.	NULL
,	NULL
Mills	NULL
,	NULL
L.	NULL
,	NULL
Lin	NULL
,	NULL
Y.-C.	NULL
,	NULL
Gerstberger	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
3021-3027	NULL
Chen	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Chug	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Blenis	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
1861-1867	NULL
S.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
807-815	NULL
Dudley	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Pang	NULL
,	NULL
L.	NULL
,	NULL
Decker	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Bridges	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Saltiel	NULL
,	NULL
A.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
1686-7689	NULL
Zhao	NULL
,	NULL
Y.	NULL
,	NULL
Bjorbaek	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Moller	NULL
,	NULL
D.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
29773-29779	NULL
Lallena	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
Diaz-Meco	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Bren	NULL
,	NULL
G.	NULL
,	NULL
Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
and	NULL
Moscat	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

19	NULL
,	NULL
2180-2188	NULL
Werlen	NULL
,	NULL
G.	NULL
,	NULL
Jacinto	NULL
,	NULL
E.	NULL
,	NULL
Xia	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

17	NULL
,	NULL
3101-8111	NULL
Monks	NULL
,	NULL
C.	NULL
R.	NULL
F.	NULL
,	NULL
Kupfer	NULL
,	NULL
H.	NULL
,	NULL
Tamir	NULL
,	NULL
L.	NULL
,	NULL
Barlow	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Kupfer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nature	NULL
385	NULL
,	NULL
83-86	NULL
.	NULL

Toullec	NULL
,	NULL
D.	NULL
,	NULL
Pianetti	NULL
,	NULL
P.	NULL
,	NULL
Coste	NULL
,	NULL
H.	NULL
,	NULL
Bellevergue	NULL
,	NULL
P.	NULL
,	NULL
Grand-Perret	NULL
,	NULL
T.	NULL
,	NULL
Ajakane	NULL
,	NULL
M.	NULL
,	NULL
Baudet	NULL
,	NULL
V.	NULL
,	NULL
Boissin	NULL
,	NULL
P.	NULL
,	NULL
Boursier	NULL
,	NULL
E.	NULL
,	NULL
Loriolle	NULL
,	NULL
F.	NULL
,	NULL
Duhamel	NULL
,	NULL
L.	NULL
,	NULL
Charon	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Kirilovsky	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
15771-15781	NULL
Martiny-Baron	NULL
,	NULL
G.	NULL
,	NULL
Kazanietz	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Mischak	NULL
,	NULL
H.	NULL
,	NULL
Blumberg	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Kochs	NULL
,	NULL
G.	NULL
,	NULL
Hug	NULL
,	NULL
H.	NULL
,	NULL
Marmé	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Schichtele	NULL
,	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
9194-9197	NULL
.	NULL

Meichle	NULL
,	NULL
A.	NULL
,	NULL
Schiitze	NULL
,	NULL
S.	NULL
,	NULL
Hensel	NULL
,	NULL
G.	NULL
,	NULL
Brunsing	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Krénke	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
83389-83438	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
.	NULL

Jamieson	NULL
,	NULL
C.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Sen	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
416-420	NULL
.	NULL

Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Tran	NULL
,	NULL
A.-C.	NULL
,	NULL
Grilli	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Science	NULL
256	NULL
,	NULL
1452-1456	NULL
.	NULL

Chen	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Rothenberg	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
228-238	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
457-460	NULL
.	NULL

Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Yoneyama	NULL
,	NULL
M.	NULL
,	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

1	NULL
,	NULL
48-49	NULL
.	NULL

Briegel	NULL
,	NULL
K.	NULL
,	NULL
Hentach	NULL
,	NULL
B.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
,	NULL
5929-5936	NULL
Kiontgen	NULL
,	NULL
F.	NULL
,	NULL
Grumont	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Strasser	NULL
,	NULL
A.	NULL
,	NULL
Metcalf	NULL
,	NULL
D.	NULL
,	NULL
Li	NULL
,	NULL
R.	NULL
,	NULL
Tarlinton	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
.	NULL

Gerondakis	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
1965-1977	NULL
Boothby	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Mora	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Scherer	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Brockman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185	NULL
,	NULL
1897-1907	NULL
Finzi	NULL
,	NULL
D.	NULL
,	NULL
Hermankova	NULL
,	NULL
M.	NULL
,	NULL
Pierson	NULL
,	NULL
T.	NULL
,	NULL
Carruth	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Buck	NULL
,	NULL
C.	NULL
,	NULL
Chaisson	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Quinn	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
Chadwick	NULL
,	NULL
K.	NULL
,	NULL
Margolick	NULL
,	NULL
J.	NULL
,	NULL
Brookmeyer	NULL
,	NULL
R.	NULL
,	NULL
Gallant	NULL
,	NULL
J.	NULL
,	NULL
Markowitz	NULL
,	NULL
M.	NULL
,	NULL
Ho	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Richman	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
and	NULL
Siliciano	NULL
,	NULL
R.	NULL
F.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
1295-1300	NULL
Coussens	NULL
,	NULL
L.	NULL
,	NULL
Parker	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Rhee	NULL
,	NULL
L.	NULL
,	NULL
Yang-Feng	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Chen	NULL
,	NULL
E.	NULL
,	NULL
Waterfield	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Francke	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
Ullrich	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Science	NULL
288	NULL
,	NULL
859-66	NULL
Knopf	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Lee	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Sultzman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Kriz	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Loomis	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Hewick	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
491-502	NULL
Baier	NULL
,	NULL
G.	NULL
,	NULL
Telford	NULL
,	NULL
D.	NULL
,	NULL
Giampa	NULL
,	NULL
L.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Baier-Bitterlich	NULL
,	NULL
G.	NULL
,	NULL
Isakov	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
4997-5004	NULL
.	NULL

Hug	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Sarre	NULL
,	NULL
T.	NULL
F.	NULL
(	NULL
19938	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

291	NULL
,	NULL
829-48	NULL
.	NULL

Lucas	NULL
,	NULL
S.	NULL
,	NULL
Marais	NULL
,	NULL
R.	NULL
,	NULL
Graves	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Alexander	NULL
,	NULL
K.	NULL
,	NULL
Parker	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
FEBS	NULL
Lett	NULL
.	NULL

and	NULL
58-56	NULL
Baer-Bitterlich	NULL
,	NULL
G.	NULL
,	NULL
Uberall	NULL
,	NULL
F.	NULL
,	NULL
Bauer	NULL
,	NULL
B.	NULL
,	NULL
Fresser	NULL
,	NULL
F.	NULL
,	NULL
Wachter	NULL
,	NULL
H.	NULL
,	NULL
Grunicke	NULL
,	NULL
H.	NULL
,	NULL
Utermann	NULL
,	NULL
G.	NULL
,	NULL
Altman	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Baier	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
1842-1850	NULL
Lin	NULL
,	NULL
X.	NULL
,	NULL
Cunningham	NULL
,	NULL
Jr.	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
Mu	NULL
,	NULL
Y.	NULL
,	NULL
Geleziunas	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
(	NULL
1999	NULL
)	NULL
Immunity	NULL
10	NULL
,	NULL
271-280	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Protein	NULL
Kinase	NULL
C	NULL
and	NULL
Calcineurin	NULL
Synergize	NULL
to	NULL
Activate	NULL
IxB	NULL
Kinase	NULL
and	NULL
NF-KB	NULL
in	NULL
T	NULL
Lymphocytes	NULL
Sergey	NULL
A.	NULL
Trushin	NULL
,	NULL
Kevin	NULL
N.	NULL
Pennington	NULL
,	NULL
Alicia	NULL
Algeciras-Schimnich	NULL
and	NULL
Carlos	NULL
V.	NULL
Paya	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:22923-22931.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.33.22923	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/33/22923	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
63	NULL
references	NULL
,	NULL
37	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

